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CHAPTER 1 
 
INTRODUCTION 
 
Obesity and metabolic disease  
The prevalence of adult and childhood obesity and associated co-morbidities 
has increased significantly in the United States (US) and other industrialized 
nations in the past several decades [1-3]. The Centers for Disease Control and 
Prevention (CDC) defines overweight and obesity relative to a person’s height by 
using the Body Mass Index (BMI) as an indicator of body fat. The range for an 
overweight individual is a BMI of 25 to 30, and for obese is a BMI of 30 and higher. 
While physicians and scientists alike acknowledge that defining obesity is more 
complicated than BMI alone, this has proven to be a useful scale for predicting 
health outcomes. With these criteria the CDC reported that 39.8% of adults and 
18.5% of children in the US were obese in 2015-2016 [6]. These data have been 
further analyzed in relation to geography, ethnicity, education, and socioeconomic 
status. As of 2017, the southeastern portion of the US shows the highest prevalence 
of obesity with seven states reporting over 35% of the adult population as obese 
(Figure 1). Hispanics and blacks reported the highest levels of obesity, and people 
with college degrees had less prominent obesity prevalence.  
! 2 
 
Figure 1. Obesity prevalence in the United States 
The Center for Disease Control and Prevention reported obesity prevalence as of 
2017. This map shows that all states had over 20% of their adult population 
considered to be obese, and seven states reporting over 35%. (www.cdc.gov) 
 
Adipose tissue depots 
 Obesity can be caused by many things, but its physiological impacts partially 
stem from excessive lipid accumulation in fat cells, called adipocytes. Adipose 
tissue (AT) has long been known to cushion and protect internal organs and to 
store excess energy as triglycerides (TG). More recently, it has become appreciated 
that AT is in fact a dynamic endocrine organ involved in crosstalk with other 
metabolic tissues [9]. With TG overload, AT expands primarily via adipocyte 
hypertrophy, although hyperplasia can also contribute. There are many AT depots, 
and the site of expansion influences whether the increased adiposity contributes to 
increased risk for development of obesity-accelerated disease (Figure 2). Distinct 
AT depots have also been identified in mice (Figure 3). 
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Figure 2. Human adipose tissue depots  
From Chusyd et al., Frontiers in Nutrition (2016) [12]. 
A) Adipose tissue (AT) depots including visceral (b: omental, c: mesenteric,  
d: retroperitoneal, e: gonadal, and f: pericardial), subcutaneous (a: abdominal,  
g: gluteofemoral, and h: intramuscular), and brown (i: supraclavicular and j: 
subscapular). B) Red color shows AT depots associated with increased obesity-
associated disease risk.  
 
Figure 3. Murine adipose tissue depots  
Adapted from Cozzo et al., Comprehensive Physiology (2018) [14]. 
Distinct adipose tissue depots and their location in mice are indicated as labeled.   
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AT depots are also described based upon the tissue “color,” on a spectrum 
from white to brown. White AT (WAT) is the most well-studied and is called such 
because of its role in TG storage, and consequent white appearance. WAT is 
characterized by adipocytes that contain a single unilocular lipid droplet (Figure 
4). Visceral AT (VAT) is WAT that surrounds organs within the peritoneal cavity 
and can be further classified as gonadal, omental, mesenteric, pericardial, and 
retroperitoneal. Of all the WAT depots, unhealthy VAT is most strongly associated 
with obesity-associated metabolic disease, such as type 2 diabetes (T2D). 
Subcutaneous AT (SAT) is found under the skin outside the peritoneal cavity, is 
less metabolically active, and is thought to be more inert with regards to disease 
risk [16, 17].  
 Brown AT (BAT) contains adipocytes with several smaller lipid droplets and 
iron-rich mitochondria that give it its characteristic brown color (Figure 4). It is 
located near the clavicle and between the shoulder blades, and is most active early 
in life. Studies of BAT function in metabolism have come to the forefront because 
BAT is capable of producing energy through non-shivering thermogenesis [18], in 
contrast to WAT’s role in storing energy. In fact, in humans it is estimated that 40-
50 grams of maximally stimulated BAT could aid in maintaining body weight by 
accounting for 20% of daily energy expenditure [19]. BAT activity occurs through 
upregulation of uncoupling protein 1 (UCP1). While the most well-studied way to 
activate this pathway is through cold exposure and resultant sympathetic nerve 
signaling and norepinephrine [20, 21], similar effects have also been seen by 
adenosine [22] and BMP8B [23] in mice, and glucocorticoids in humans [24].  
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Figure 4. Schematic of white, beige, and brown adipocytes in mice  
From Wang & Seale, Nature Reviews Molecular Cell Biology (2016) [25]. 
Characteristic summary of different types of murine adipocytes, their function, and 
their thermogenic potential. Differential lipid droplet size is also shown via 
histology.  
 
A goal of investigators is to manipulate white adipocytes to resemble brown 
adipocytes in order to burn energy more efficiently, a process termed “beiging” [18, 
26] (Figure 4). UCP1 activation in white adipocytes has been shown to be 
activated through expression of BMP4 [27], COX [28], FGF21 [29], and treatment 
with β3-adrenergic receptor [30] or PPARγ [31, 32] agonists. In mice, the 
inguinal/subcutaneous AT depot shows the most promising capability of beiging to 
increase energy expenditure [33], although it has also been reported that gene 
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expression patterns may differ between mice and humans [34]. Many other 
proteins have been implicated for their role in BAT activation and/or beiging 
potential [26], and this is area of continued research in the metabolism field [35].  
 
Obesity-associated disease 
Obesity has been shown to contribute to pathologies associated with many 
diseases including asthma [36], arthritis [37, 38], cardiovascular disease (CVD) 
[39], chronic obstructive lung disease [40], inflammatory bowel disease [41], 
kidney disease [42], neurodegeneration [43-45], non-alcoholic fatty liver disease 
(NAFLD) [46], T2D [47, 48], and some types of cancer [49-52]. It is associated 
with a state of chronic low-grade inflammation accompanied by elevated 
circulating levels of pro-inflammatory cytokines that lead to insulin resistance (IR) 
in AT, muscle, and liver [53-56]. Whether the inflammatory nature of AT in obesity 
contributes to systemic inflammation and the development of the chronic diseases 
listed above is an area of ongoing investigation by laboratories around the world. 
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Insulin action and resistance 
Upon exposure to glucose, the body seeks to normalize blood sugar levels by 
stimulating glucose uptake via insulin signaling. In healthy individuals, when 
glucose enters the bloodstream, the pancreas responds by secreting insulin. Insulin 
binds to its receptor, INSR, on cells in metabolic tissues including AT, brain, liver, 
muscle, and pancreas. INSR is a transmembrane tyrosine kinase receptor that is 
activated upon ligand binding, leading to autophosphorylation of the receptor. 
Activation leads to recruitment of adaptor proteins, and these facilitate signaling 
(Figure 5) [57, 58]. Consequent downstream actions result in phosphorylation 
and activation of Akt, which can lead to diverse endpoints. Akt can activate Foxo 
family proteins to induce gluconeogenesis, lipid synthesis, and transcription 
involved in hepatic glucose control. It also induces activation of the mTORC1 
complex to activate other targets involved in genetic regulation of protein 
synthesis, and inactivates GSK3 to regulate hepatic glycogen stores. It can mediate 
cell growth and survival by controlling members of the p53 and NFκB pathways. 
Insulin-stimulated signaling is also regulated in a tissue-dependent manner. The 
main downstream effect of insulin signaling in AT is inhibition of lipolysis, in 
skeletal muscle is glucose uptake via GLUT4, and in liver is regulation of hepatic 
glucose output. During IR, tissues do not effectively sense insulin, leading to 
impaired insulin signaling and reduction of insulin’s positive metabolic effects.  
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Figure 5. Insulin signaling through insulin receptor  
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Adipose tissue immunometabolism 
 There are several mechanisms by which impaired insulin action can occur, 
but the focus of the Hasty Lab is to determine the role of obesity-associated 
inflammation. Thus far, this introduction has focused on AT depots and different 
types of adipocytes. AT also contains many other cell types, and these populations 
change with the onset and progression of obesity. AT was one of the first organs in 
which macrophage contribution to metabolic disease was discovered, and is 
arguably the best studied. Less than 20 years ago it was found that the number of 
macrophages increases in obese compared to lean AT and that this imparts an 
overall inflammatory milieu [59, 60]. Macrophage recruitment requires the 
assistance of inflammatory cytokines, which are secreted by adipocytes, 
macrophages themselves, and various other immune cells. These cytokines can 
also interfere with insulin signaling, resulting in IR of AT. For example, IFN-γ 
treatment of human adipocytes leads to down-regulation of INSR and decreased 
activation of the downstream effector, AKT [61]. Similarly, 3T3-L1 adipocytes 
treated with IL-6 exhibited decreased expression in insulin signaling pathway 
proteins [14, 62], and with TNF-α even showed blunted autophosphorylation of the 
INSR [63]. These effects ultimately result in the down-regulation of GLUT4 and 
decreased glucose uptake. Ultimately, cytokine-induced IR can lead to unchecked 
basal lipolysis and ectopic lipid storage in other metabolic tissues such as muscle 
and liver.  
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Immunophenotype of white adipose tissue 
Aside from macrophages, many other immune cells secrete cytokines and 
are involved in inflammatory responses. Since the seminal AT macrophage 
publications by Weisberg and Xu in 2003 [59, 60], these cell types have been 
evaluated for their involvement in AT homeostasis [64, 65]. A simplified schematic 
of the immunometabolic landscape of WAT is described in Figure 6. Specifically, 
eosinophils [66], M2-like anti-inflammatory and iron-containing MFehi 
macrophages [67], regulatory B cells [68, 69], and natural killer [70] and 
regulatory T cells [71, 72] are resident in lean WAT. In contrast, B cells [73, 74], 
dendritic cells [75], pro-inflammatory M1-like macrophages [76], mast cells [77], 
neutrophils [78], and CD4+ and CD8+ T cells [79, 80] infiltrate WAT with obese 
conditions.  
 
Figure 6. Immune cells of white adipose tissue  
The microenvironment of adipose tissue changes with the onset and progression of 
obesity. 
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Immunophenotype of brown adipose tissue 
The immune cell repertoire of BAT is much less studied than WAT. There is 
evidence of the presence of various immune cell types in BAT, such as eosinophils 
[66], macrophages and monocytes [81], and regulatory T cells [82], but many of 
these studies were carried out as supporting data to studies on WAT. This gap in 
the field led to the studies presented in Chapter 2 of this Dissertation, and the most 
recent discoveries regarding the immunophenotype of BAT are highlighted in the 
final discussion in Chapter 4 of this Dissertation. 
 
Complement in adipose tissue inflammation 
 Cytokines play a central role in obesity-induced inflammation, but another 
major contributor is the complement system. The complement system is a vital 
component of both innate and adaptive immune responses and is conserved across 
a wide range of species [83]. Three different complement activation pathways have 
been described: classical, alternative, and lectin-binding [84]. In addition to AT, 
other sites of complement factor secretion include the liver and gastrointestinal 
tract. Complement proteins remain inert in the circulation until activated, at which 
time an amplified cascade of proteolytic steps results in cleavage of complement 
factor 3 (C3) into C3a and C3b, as well as complement factor 5 (C5) into C5a and 
C5b (Figure 7). C3a and C5a are further modified into their desarginated forms, 
C3adesArg and C5adesArg, respectively. C5a is the most potent anaphylatoxin of the 
complement cascade, and has many functions in the immune system: it is a strong 
chemoattractant for all cells of the myeloid lineage and some cells of the lymphoid 
lineage [85], it has been shown to modulate cytokine expression in various cell 
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types [86], and it up-regulates adhesion molecules in neutrophils, monocytes and 
epithelial cells [87]. C5b binds to the membrane of target cells, serving as an 
anchor for the sequential binding of C6, C7, C8, and C9. This leads to the formation 
of the membrane attack complex (C5b-9) and subsequent cell lysis. Each of these 
functions can further exacerbate obesity-associated inflammation in AT, and 
Chapter 3 will delve into further detail about these topics.  
 
 
Figure 7. Complement signaling pathway 
From Trouw et al., Nature Reviews Rheumatology (2017) [88]. 
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Conclusion 
 Obesity and associated diseases have become public health problems of 
epidemic proportions. The associated AT inflammation has become a major focus 
of the Immunometabolism field, but there are still many questions to be answered 
and discoveries to be made. The remainder of this Dissertation details my 
contributions to the field by evaluating the immunophenotype of BAT (Chapter 2) 
and how complement factor 5 is involved in systemic metabolism (Chapter 3). It 
will conclude with a discussion (Chapter 4) of how these findings contribute to the 
field and where the future questions may lead. An additional appendix is included, 
which is a review article describing the potential of macrophage-targeted 
therapeutics in the treatment of metabolic disease (Appendix).  
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CHAPTER 2 
 
THE IMMUNOPHENOTYPE OF BROWN ADIPOSE TISSUE 
This chapter was adapted from a published article titled, 
Obesity alters B cell and macrophage populations in brown adipose tissue 
written by Peterson, Flaherty, and Hasty [89]. 
 
Introduction 
Properly functioning WAT is vital for systemic metabolic homeostasis. 
While WAT is appreciated for its role in organ protection and energy storage, 
BAT’s evolutionary purpose is to aid in temperature regulation of animals through 
UCP1-driven thermogenesis. As BAT has become better understood, there has been 
more of a focus on the potential for beiging of WAT to burn energy and combat 
obesity. While this strategy shows obvious health benefits, there is not enough 
known about the physiology of BAT and how the tissue environment is involved in 
thermogenesis.  
It is well-established that inflammation and associated immune cells have 
an important role in WAT homeostasis and progression to obesity-induced disease 
(Figure 6) [64, 65]. Accordingly, it is important to understand the role of immune 
cells in BAT in both obesity and aging to determine how they will be affected with a 
therapeutic goal of WAT beiging. Immune signaling in BAT has not been 
systematically studied, and the knowledge about the immune cell repertoire of BAT 
is limited. Because of this lack of systematic understanding, we used an 
“immunophenotyping” approach to determine which cell types are present. This 
information will be vital for further comparing the function of BAT in normal and 
diseased states.   
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Methods 
Mouse studies 
Animal procedures were performed following IACUC approval. Male and 
female C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, 
ME) and aged or fed special diets in the Vanderbilt facility. Mice were maintained 
on chow diet for the aging studies (1, 6-7, or 10-15 months) and on 10% low fat diet 
(LFD) or 60% high fat diet (HFD) (Research Diets, Inc. New Brunswick, NJ) for 3, 
8, or 16 weeks for the obesity studies. Mice were fed ad libitum. Upon termination 
of the study, BAT was harvested by cutting away connecting tissue that looked 
more like WAT.  
 
Flow cytometry  
 Stromal vascular fraction (SVF) of the total BAT from one animal per sample 
was collected following collagenase digestion and centrifugal separation as 
previously described [90]. Briefly, BAT was digested for 4 h with 2 mg/mL 
collagenase type 4 (Worthington, Lot #45H15909). The tissue was pressed through 
a 100 µm filter. The isolated SVF was incubated with Fc block for 5 min on ice, 
washed, and incubated with fluorophore-conjugated antibodies for 20 min at 4 ̊C. 
The following antibodies were used: B220-FITC, CD3-APC/Cy7, CD45-PE/Cy7, 
F4/80-APC, and SiglecF-PE (BD Biosciences, Franklin Lakes. NJ). DAPI was used 
for viability staining. Flow cytometry was carried out on the entire volume from 
each sample at the Vanderbilt Flow Cytometry Shared Resource using a BD Special 
Order Research Product (SORP) LSR Fortessa. Please see Figure 8 for the gating 
scheme. 
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Figure 8. Flow cytometry gating scheme. 
Leukocytes were identified initially by their forward scatter (FSC) and side scatter 
(SSC) properties. Subsequent FSC and SSC pulse geometry gates were used to 
eliminate aggregating cells. Viable leukocytes were identified as DAPI-, CD45+ 
cells. From CD45+ cells, the analysis of B cells (B220+, F4/80-) and macrophages 
(B220-, F4/80+) was achieved by using a dot plot. Eosinophils were gated from 
CD45+ leukocytes as F4/80+ and SiglecF+.  
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Histology & imaging 
BAT tissue was fixed in 10% formalin overnight, paraffin embedded, 
sectioned, and stained by the Vanderbilt Translational Pathology Shared Resource 
for hematoxylin and eosin, CD11b (macrophages), and B220 (B cells). Images were 
captured and analyzed through the Vanderbilt Digital Shared Resource and Leica 
Digital Image Hub software.  
 
Statistical analysis 
All statistics were performed using GraphPad Prism software. BAT mass 
changes and all LFD:HFD cell population comparisons were analyzed by unpaired 
Student’s t-test. Aging-associated differences and body weight curves were 
analyzed by one-way and two-way ANOVA, respectively.  
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Results 
Metabolic parameters of mice on diet 
Male and female wild type C57BL/6J mice gained weight on HFD (Figure 
9A-B). In addition to WAT expansion, BAT mass was also increased and was 
significantly greater in mice fed HFD for 8 and 16 weeks (Figure 9C-D).   
 
Figure 9. Metabolic parameters of mice on diet.  
Wild type C57BL/6J mice were placed on 10% low fat diet (LFD) or 60% high fat 
(HFD) for 3, 8, or 16 weeks. Body weight was measured weekly (A: male, B: 
female), and brown adipose tissue was collected and weighed (C: male, D: female). 
Data are presented as mean ± SEM of 4-5 samples per group. 
+ p<0.05; ++ p<0.01; +++ p< 0.001; ++++ p< 0.0001 
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Flow cytometry of brown adipose tissue stromal vascular fraction 
BAT SVF was analyzed for the presence of B cells, macrophages, and 
eosinophils using flow cytometry (see Figure 8 for gating scheme). CD45+ 
leukocytes represent less than 5% of all live cells. In general, there is a higher 
frequency of B220+ B cells (Figure 10A-B) and a lower frequency of F4/80+ 
macrophages (Figure 10C-D) in HFD- compared to LFD-fed mice.  
 
Figure 10. Flow cytometry of brown adipose tissue (BAT) stromal 
vascular fraction (SVF).  
BAT was collected from wild type C57BL/6J mice after 3, 8, or 16 weeks of 10% low 
fat diet (LFD, white bars) or 60% high fat (HFD, black bars). SVF was processed 
and analyzed by flow cytometry for B220+ B cells (A: male, B: female) and F4/80+ 
macrophages (C: male, D: female) as a percent of CD45+ live cells. Data are 
presented as mean ± SEM of 4-5 samples per group. 
+ p<0.05; ++ p<0.01; +++ p< 0.001 
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Concomitantly, there is a lower frequency of SiglecF+ eosinophils in animals 
with diet-induced obesity (Figure 11). The data show that 13.5% ± 2.1 of live 
leukocytes are SiglecF+ in male mice fed HFD, while 6.9% ± 1.5 (p<0.05) are 
SiglecF+ in mice fed LFD for 8 weeks.  
 
Figure 11. Flow cytometry of brown adipose tissue (BAT) stromal 
vascular fraction (SVF).  
BAT was collected from wild type C57BL/6J mice after 8 weeks of 10% low fat diet 
(LFD, white bars) or 60% high fat (HFD, black bars). SVF was processed and 
analyzed by flow cytometry for SiglecF+ eosinophils (A: male, B: female) as a 
percent of CD45+ live cells. Data are presented as mean ± SEM of 5 samples per 
group. 
+ p<0.05 
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The very low prevalence of B220+ B cells and CD11b+ macrophages was 
confirmed by immunohistochemical staining of BAT from male wild type animals 
fed LFD or HFD for 8 weeks (Figure 12). 
 
Figure 12. Brown adipose tissue (BAT) immunohistochemistry.  
BAT was collected from wild type C57BL/6J mice fed 10% low-fat (LFD) or 60% 
high-fat (HFD) diet for 8 weeks, and fixed in 10% formalin before further 
processing and staining for hematoxylin & eosin (H & E), CD11b+ (macrophages), 
or B220+ (B cells). Red arrows indicate positively stained cells. Data presented are 
representative images from 3 samples per group. 
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Analysis of brown adipose tissue immune cells with aging 
Additionally, the effect of aging on BAT immune cell repertoire was 
investigated. Body weights increased with age, and mice that were 6-7 month and 
10-15 months old were significantly heavier than mice that were only 1 month old 
(p<0.0001; Figure 13A-B). BAT mass increased with age in the male, but not the 
female, mice in a similar pattern as the body weight (p<0.01; Figure 13C-D).  
 
Figure 13. Analysis of brown adipose tissue (BAT) with aging. 
Male and female wild type C57BL/6J mice were aged to 1, 6-7, or 10-15 months. 
Their final body weight was measured (A: male, B: female), and BAT was collected 
and weighed (C: male, D: female). Data are presented as mean ± SEM of 4-18 
samples per group. 
* p<0.05; ** p<0.01; **** p<0.0001 
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The SVF was analyzed by flow cytometry and there were no observed 
changes in B cell or macrophage repertoires in response to aging (Figure 14A-B).  
Figure 14. Analysis of brown adipose tissue (BAT) immune cells with 
aging. 
Male and female wild type C57BL/6J mice were aged to 1, 6-7, or 10-15 months. 
BAT stromal vascular fraction was processed and analyzed by flow cytometry for 
B220+ B cells (non-patterned bars) and F4/80+ macrophages (striped bars) as a % 
of CD45+ live cells (A: male, B: female). Data are presented as mean ± SEM of 4-18 
samples per group. 
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Discussion 
Our data show that macrophages, eosinophils, and B cells are present in 
BAT, cumulatively making up about 75% of the CD45+ immune cell population. 
While previous reports have shown that eosinophils [66] and macrophages [81] are 
present in BAT, to our knowledge, this is the first report of the presence of B cells. 
We show a higher frequency of B cells in obese compared to lean mice, while 
macrophages and eosinophils show the opposite trend. These trends are present in 
both sexes, but the males do not appear to have as strong of a diet-driven effect.  
Previous studies have assessed macrophages in BAT by flow cytometry with 
markers such as Cx3Cr1, F4/80, CD14, CD64, MerTK, and MHCII [91]. During the 
preparation of our manuscript, Wolf et al. beautifully showed that during 
development, most BAT macrophages are CX3CR1+MCHII-, but that they 
progressively form 4 distinct populations based upon CX3CR1 and MCHII 
expression [91]. While our data showed a reduction in the percent of macrophages 
in BAT in obese mice, we did not see changes during aging. The understanding of 
aging WAT is that it becomes more inflammatory, with a similar phenotype to 
obese AT [92]. With these studies however, we cannot rule out phenotypic changes 
associated with aging, as we did not assess gene expression patterns of CX3CR1, 
MHCII levels, or polarization markers.  
The underlying tone of some work on BAT macrophages has been that they 
exist in relatively high numbers in the BAT and that they play an important role in 
BAT physiology. However, in our studies, we show that macrophages make up only 
30% of the BAT immune cell population, which is already less than 5% of all live 
cells. Published studies showing histology for macrophages in BAT also show low 
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numbers. Buettner and colleagues reported that Mac-2-positive macrophages exist 
in only small numbers in BAT [93] and Czeck and colleagues did not observe any 
F4/80+ macrophages in BAT [94]. It has also been reported that the inflammatory 
nature of macrophages in diet-induced obesity is lower in BAT compared to WAT, 
and we in fact detected a reduction in BAT macrophage percentage in obese mice. 
Furthermore, Dowal et al. have shown that co-culture of macrophages with brown 
adipocytes has little impact on their inflammatory nature [95]. The function of BAT 
macrophages in homeostasis or in pathogenesis is not yet clear. A role for BAT 
macrophages in catecholamine synthesis and adaptive thermogenesis was 
suggested by one group [96] but was recently disputed [93]. Certainly, 
macrophages are important cells for tissue homeostasis; however, given their very 
low numbers, the lack of changes in gene expression of macrophages co-cultured 
with brown adipocytes, the absence of change with obesity or aging, and the recent 
publication showing no effect of M2 macrophages on catecholamine synthesis or 
adaptive thermogenesis [93], the physiological function of BAT macrophages is 
unclear. 
Interestingly, we found that 20-30% of leukocytes in BAT are B cells. While 
B cells have traditionally been studied for their role in antigen processing and 
antibody secretion, their immunoregulatory role has surfaced in the context of 
inflammatory disease. B cell phenotypic plasticity is influenced by both 
norepinephrine [97] and adenosine [98], which are also known to activate 
thermogenesis in BAT. Additionally, norepinephrine is released in response to 
antigen presentation, and is necessary for normal expression of IgG [99]. Further 
studies are needed to characterize BAT B cells and their role in this tissue.   
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Due to the paucity of immune cells in BAT, we limited our analyses to 
macrophages, eosinophils and B cells. However, future studies could provide a 
more detailed analysis of their phenotype, as well as reveal other immune 
populations. Despite these limitations, our work adds to the field’s quantification 
of immune populations in BAT, especially with the addition of B cells.  
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CHAPTER 3 
 
THE ROLE OF COMPLEMENT FACTOR 5 IN METABOLISM 
This chapter was adapted from an article under review titled, 
Impaired insulin signaling in the B10.D2-HC0 H2Dd H2-T18c/oSnJ 
mouse model of complement factor 5 (C5) deficiency 
written by Peterson, Gutierrez, Kikuchi, Anderson-Baucum, 
Winn, Shuey, Bolus, McGuinness, and Hasty. 
 
Introduction  
 While much work has focused on the role of specific cytokines and 
chemokines in obesity-associated inflammation, very little is known regarding the 
contribution of primitive components of immunity, such as the complement 
system, to systemic metabolic regulation. The complement system is an 
evolutionarily conserved arm of the innate immune system that when activated can 
promote inflammation and cell lysis. Various cells, including hepatocytes, 
epithelial cells of the gastrointestinal tract, adipocytes, and immune cells secrete 
complement proteins, which remain inert in circulation until activated (Figure 7). 
Studies suggest that, in addition to their key function in immunity (described in 
Chapter 1), products of the complement system also play a vital role in metabolism. 
Complement proteins are associated with the onset and progression of obesity-
associated inflammation in AT, attributed in part to their chemoattractive 
properties [100]. Alternatively, studies have also demonstrated complement 
proteins to be important in metabolism, partially due to their ability to promote 
glucose uptake by various cell types, including adipocytes [101-108]. These 
contrasting properties, as well as our data showing increased Hc (i.e. C5 gene 
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name) expression in diet-induced obese mice (Figure 15), led to the experiments 
shown here investigating how C5 deficiency influences systemic metabolism. 
 The mouse strain most commonly used to study the effects of isolated C5 
deficiency is the Jackson B10.D2-Hc0 H2d H2-T18c/oSnJ, henceforth referred to as 
C5def. There are several other mouse strains known to be C5 deficient. They are 
historically used in other areas of physiology and disease, such as alcohol tolerance 
(DBA/2J) [109], arthritis (DBA/1J) [110], atherosclerosis susceptibility (AKR/J, 
A/J, CBA/J, DBA/2J) [111-113], cancer susceptibility (AKR/J, A/J) [114, 115], 
diabetes and obesity (AKR/J, NOD/ShiLtJ) [116, 117], eye defects (CBA/J, 
DBA/2J, FVB/NJ) [118-120], and hearing defects (AKR/J, A/J, CBA/J, DBA/1J, 
DBA/2J, NOD/ShiLtJ) [121-123]. Many of these models are known to have genetic 
variability at other loci in addition to C5, but the B10.D2-Hc0 H2d H2-T18c/oSnJ 
C5def strain used in the current study is reported as the model with the least 
confounding variables. The metabolic phenotype of C5 deficient AKR/J and 
NOD/ShiLtJ mice has been previously evaluated; however, that of B10.D2-Hc0 H2d 
H2-T18c/oSnJ C5def mice has not. The NOD/ShiLtJ mouse is well known as a 
model for type 1 diabetes. While it is C5 deficient, it also has other well-
characterized defects in other immune pathways such as general cytokine 
production and adaptive immune responses (www.jax.org/strain/001976). The 
AKR/J mouse is commonly used in cancer biology because of its susceptibility to 
leukemia. In addition to being C5 deficient, it is also reported to have genetic 
variation in at least ten other genes (www.jax.org/strain/000648). For these 
reasons, we chose to focus our studies on the C5def B10.D2-Hc0 H2d H2-T18c/oSnJ 
strain.  
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 In the current study, we evaluated the effects of primary deficiency of 
circulating C5 on insulin sensitivity in mice. We showed that C5def mice exhibited 
severe glucose intolerance and systemic IR in both lean and obese states that was 
inflammation-independent. IR in the C5def mouse strain was associated with a 
genetic mutation in the Insr gene and improper processing of the pro-insulin 
receptor in multiple metabolically-active tissues, as has been reported in other 
models of INSR haplodeficiency [124]. Interestingly, adenoviral overexpression of 
C5 improved insulin sensitivity in both C5cont and C5def mice, lending support for a 
beneficial role of C5 in metabolism. 
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Methods 
Mice and diets  
All animal procedures were performed after approval from the Institutional 
Animal Care and Use Committee of Vanderbilt University (VU).  All mice were 
purchased from The Jackson Laboratory (Jx, Bar Harbor, Maine). The congenic C5 
deficient (C5def) mice were originally generated at Jx by crossing the naturally C5def 
DBA/2J mice onto the C57BL/10SnJ background for more than 10 generations and 
selecting for the Hc0H2d and H2-T18c loci; thus generating the B10.D2-Hc0 H2d 
H2-T18c/oSnJ congenic strain utilized in this study. C5def mice have a 2-base pair 
deletion in Exon 6 of the C5 gene that leads to an early stop codon, thus rendering 
the mice C5 deficient [125-127]. Mice wild type for C5, B10.D2-Hc1H2dH2-
T18c/oSnJ, referred to as C5cont, were used as controls. Eight-week old C57BL/6J 
mice were placed on 10%, 45% or 60% fat diets (Research Diets, Inc. New 
Brunswick, NJ, Catalog #D12492, D12451, and D12450J, respectively) for 16 
weeks. Eight-week old C5def and C5cont mice were placed on either a 10% low fat 
diet (LFD) or 60% high fat diet (HFD) for up to 12 weeks. AKR/J, DBA/2J, A/J, 
CBA/J, DBA/1J, FVB/NJ, and NOD/ShiLtJ mice were purchased from Jackson 
Laboratory and maintained on chow diet in VU facilities prior to experiments at 8-
12 weeks of age. Male mice were used in all experiments unless indicated 
otherwise. Mice were kept in the VU non-barrier facility, fed ad libitum and given 
free access to water. 
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Body weight, body composition, and food intake 
Body weight was measured weekly for the duration of the study. Total lean 
mass, AT mass and free fluid composition were measured by nuclear magnetic 
resonance using a Bruker Minispec (Woodland, TX) in the Vanderbilt Mouse 
Metabolic Phenotyping Center (MMPC) at baseline and 6 and 12 weeks after 
placement on the respective diet.  
 
Blood collection and analyses   
Mice were fasted for 5 h and bled from the retro-orbital venous plexus using 
heparinized collection tubes. Glucose levels from whole blood were measured using 
a LifeScan One Touch Ultra glucometer (Johnson & Johnson, Northridge, CA). 
Plasma was separated by centrifugation and stored at -80 ̊C until further analysis. 
Plasma insulin levels were measured using an ELISA or by radioimmunoassay 
from Millipore (Billerica, MA).  
 
Glucose tolerance test  
Mice were morning-fasted for 5 h before the initiation of the test. Mice were 
bled via tail snip and baseline glucose was measured using a glucometer. Mice were 
then injected with 1 g of dextrose per kg of lean body mass. Glucose levels were 
assessed at 15, 30, 45, 60, 90, 120, and 150 min after glucose injection. 
 
Hyperinsulinemic-euglycemic clamps  
One week before hyperinsulinemic-euglycemic clamps were performed, 
mice had carotid artery and jugular vein catheters surgically implanted for 
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sampling and infusions, respectively. On the day of a study, mice were fasted for 5 
h and insulin clamps were performed in conscious unrestrained mice as previously 
described [128, 129]. Two hours prior to the clamp a primed (1 µCi) continuous 
(0.05 µCi/min) tracer ([3-3H]-glucose) infusion was initiated and continued for the 
duration of the study. After baseline blood samples for insulin and tracer 
measurements insulin was infused (t=0 min) at 2.0 mU·kg-1·min-1. Glucose was 
infused at a variable rate to maintain euglycemia. After 120 min a bolus of 
2[14C]deoxyglucose (2DG) was administered, and after 25 min had elapsed, tissues 
were collected. 2DG was used to determine the glucose metabolic index (Rg), a 
measure of tissue-specific glucose uptake [130, 131]. Washed blood cells from a 
donor animal were continuously infused to maintain blood volume during the 
clamp.     
 
Tissue collection and weights  
At the end of each study, brain, epididymal AT, liver, gastrocnemius muscle, 
and pancreas were collected, weighed, and snap-frozen in liquid nitrogen. For 
clamp studies additional tissues were collected to determine glucose uptake 
including BAT, inguinal WAT, heart, soleus muscle, and vastus lateralis muscle,  
 
Real-time RT-PCR  
Tissue RNA isolation and cDNA synthesis were performed as previously 
described [132]. FAM-conjugated primer/probe sets were purchased from Applied 
Biosystems (Foster City, CA). Catalog numbers will be provided upon request.  All 
genes were normalized to glyceraldehyde-3-phosphate dehydrogenase expression, 
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and presented as expression relative to the C5cont group fed a 10% fat diet (LFD). 
Data were analyzed using the Pfaffl method [133].  
 
Western blot analysis   
Protein samples were collected by sonicating 50 mg of AT, liver, or 
gastrocnemius muscle in 2% SDS. Protein concentration was measured using a 
BCA assay, and equal concentrations of total protein were run on 4-20% SDS gels 
(BioRad) or 4-12% Bis Tris gels (Invitrogen), transferred to nitrocellulose 
(Invitrogen) or PVDF (BioRad) membranes, and immunoblotted for the indicated 
probes of interest (antibodies from Cell Signaling: 3020, 3700, 4060, 9272). The 
blots shown in figures 28, 31, 32, 33, 34, and 36 were visualized by enhanced 
chemiluminescence (Amersham Pharmacia BioTech). The blots shown in figures 
35, 37, and 43 were visualized by fluorescently-tagged secondary antibodies (Li-
Cor) and imaged on the Li-Cor Odyssey in the Vanderbilt Molecular Cell Biology 
Resource Core. Quantification of the intensity of individual bands was done using 
ImageJ. 
 
Tissue histology  
Liver: Liver samples were collected, frozen in Optimal Cutting Temperature 
(OCT) solution, and stored at -20 ̊C. Seven micrometer sections of liver were cut 
using a cryostat and stained for Oil Red O. Images were captured using an 
Olympus BX51 microscope (Tokyo, Japan) at a 10X magnification. Adipose: 
Epididymal AT samples were collected and fixed in 10% formalin overnight. They 
were further processed, paraffin embedded, and sections were cut and stained with 
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anti-F4/80 antibody by the Vanderbilt Translational Pathology Shared Resource. 
Entire slides were imaged on a Leica SCN400 Slide Scanner by the Vanderbilt 
Digital Histology Shared Resource (DHSR) at a 20X magnification. F4/80 positive-
stained crown-like structures (CLS) were counted per field of view using ImageJ 
public software.  
 
DNA isolation, whole genome sequencing, and read alignment 
Total DNA was isolated from liver of C5cont and C5def male mice according to 
the DNeasy Blood & Tissue Kit (Qiagen). Samples were submitted to the Vanderbilt 
Technologies for Advanced Genomics (VANTAGE) resource core for quality control 
and sequencing. Before processing, genomic DNA samples undergo quality control 
testing in the form of Qubit and Tapestation runs following manufacturer’s 
protocols. Samples are normalized, sheared (Covaris LE220) and Illumina ready 
libraries are prepared (NEB DNA Ultra II). Final libraries are assessed for quantity 
and quality using Qubit and Qiagen QIAxcel runs. Successful libraries are 
normalized and subjected to Kapa qPCR. Libraries are pooled and loaded on 
the NovaSeq6000 following Illumina protocols and fastq files are generated from 
raw sequence data using Illumina’s bcl2fastq software. Fastq reads are analyzed via 
FastQC for sequence quality, GC content, the presence of adaptors, 
overrepresented k-mers and duplicated reads in order to detect sequencing errors, 
PCR artifacts or contaminations. Reads are also mapped to the reference genome 
(when available) for additional contamination assessment. 
 Sequencing reads after quality control were mapped to the C57BL/6J 
reference genome (NCBI build M37/mm9) using the Burrows-Wheeler aligner 
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(BWA-MEM v0.7.17 [134]) on a per-mouse basis using default parameters. Using 
SAMtools [135], aligned SAM files were converted to BAM files that were re-sorted 
and then indexed. Visualization of the Insr gene using the Integrated Genomics 
Viewer (IGV.2.4.14 [136]) was used for the initial identification of variation 
between the control and case genes. The variants and indels in Insr gene identified 
during the visualization process were confirmed in the consensus sequences, which 
were created using the SAMtools mpileup function and BCFtools for each genome 
[135]. 
 
Adenoviral studies 
Preparation of adenovirus: Adenovirus (Ad5 with E1/E3 deletion) 
containing human C5 (clone BC113738) was purchased from Vector BioLabs. 
Adenovirus containing GFP was used as the control. Mice were fed 10% LFD for 14-
16 weeks prior to AdC5 or AdGFP injection. Adenovirus was provided at 1.1x109 
PFU/mouse in 200 µL PBS via the retro-orbital venous plexus. Four weeks 
following adenovirus injection, hyperinsulinemic-euglycemic clamps were 
performed as described above.  
 
Statistical analyses   
All statistics were performed using GraphPad Prism software. Given the 
multiple models used herein, details pertaining to statistical analyses are provided 
in each figure legend. 
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Results 
Regulation of complement expression by HFD feeding 
To determine the effects of obesity on expression of components of the 
complement system, male C57BL/6J mice were fed diets containing 10%, 45%, or 
60% of kcals from fat for 16 weeks. AT gene expression of complement factor 5 
(Hc) was elevated with increasing dietary fat composition: mice fed a 60% fat diet 
had a >10-fold increase in AT Hc expression when compared to mice fed a 10% fat 
diet (p<0.0001; Figure 15A).  In contrast, AT expression of C3, C9, and Factor B 
(Cfb) were unchanged (Figure 15B-D), while C6 and Factor D (Cfd) expressions 
were decreased with increasing fat in the diet (p<0.01; Figure 15E-F).  
 
Figure 15. Regulation of adipose tissue complement expression by HFD 
feeding 
C57BL/6J mice were placed on 10%, 45% or 60% fat diets for 16 weeks.  Adipose 
tissue was collected and total mRNA expression was assessed by real-time RT-
PCR. A) Hc, B) C3, C) C9, D) Cfb, E) C6, F) Cfd. Data are presented as mean ± SEM 
of 4-7 mice per group, and were analyzed by one-way ANOVA with multiple 
comparisons. 
++ p<0.01; +++ p<0.001; ++++ p<0.0001  
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 In the liver, HFD feeding did not change the expression of Hc, C3, or C9, but 
reduced the expression of C6 (p<0.05 compared to 10% fat diet; Figure 16A-D). 
These data indicate that components of the complement system are dynamically 
regulated by obesity and dietary fat content.   
 
Figure 16. Regulation of liver complement expression by HFD feeding 
C57BL/6J mice were placed on 10%, 45% or 60% fat diets for 16 weeks.  Liver was 
collected and total mRNA expression was assessed by real-time RT-PCR. A) Hc, B) 
C3, C) C9, D) C6. Data are presented as mean ± SEM of 4-7 mice per group, and 
were analyzed by one-way ANOVA with multiple comparisons. 
+ p<0.05  
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Metabolic characterization of C5def mice  
 Because Hc gene expression was the only complement factor whose 
expression was elevated in obese AT, we next determined whether deficiency in its 
encoded protein, C5, abrogates obesity-associated inflammation and metabolic 
dysfunction in mice. Accordingly, C5 control (C5cont) and C5 deficient (C5def) mice 
were placed on a 10% fat LFD or 60% fat HFD for 12 weeks to evaluate their 
metabolic phenotypes. C5 deficiency did not alter weight gain or final body weights 
in mice fed LFD (Figure 17A). In contrast, as soon as 2 weeks after beginning 
HFD feeding, C5def mice weighed less than C5cont mice (p<0.05). Food 
consumption was not statistically different between genotypes (data not shown). 
After 12-weeks of HFD feeding, both groups had increased AT mass (p<0.0001); 
however, C5def mice had less total AT mass than the C5cont animals (p<0.0001; 
Figure 17B). Total lean mass and liver mass were elevated by HFD feeding in the 
C5cont mice (p<0.001 and p<0.01, respectively) but not in the C5def mice (Figure 
17C-D).  
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Figure 17. Metabolic characterization of C5cont and C5def mice  
C5 control (C5cont) and C5 deficient (C5def) mice were placed on LFD or HFD for 12 
weeks. A) Body weight curves. B) Total adipose tissue mass as measured by NMR. 
C) Total lean mass as measured by NMR. D) Liver weight.  Data are presented as 
mean ± SEM of 11-14 mice per group, and were analyzed by two-way ANOVA with 
multiple comparisons, and body weight curve with repeated measures.  
* p<0.05; ** p<0.01; **** p<0.0001 (genotype effect) 
++ p<0.01; +++ p<0.001; ++++ p<0.0001 (diet effect) 
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Tissue inflammation and physiology  
 To determine if C5def mice display differences in tissue inflammation, RNA 
was isolated from epididymal AT and liver after 12-weeks of LFD or HFD feeding, 
and gene expression of macrophage and inflammatory markers was analyzed by 
quantitative real-time RT-PCR. Based upon expression of Emr1 (gene for F4/80), 
AT macrophage content was significantly increased by HFD-feeding in both groups 
(p<0.01 for C5cont, p<0.05 for C5def; Figure 18A). Expression of the cytokines Tnf, 
Il10, and Ccl2 also showed the expected increase with HFD feeding in both C5def 
and C5cont AT (p<0.001 for Tnf; p<0.01 C5cont and p<0.05 C5def for Il10; p<0.001 
C5cont and p<0.01 C5def for Ccl2; Figure 18B-D). There was a trend toward 
reduced AT expression of Emr1, Il10, and Ccl2 in C5def compared to C5cont mice, 
this did not reach statistical significance.  
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Figure 18. Adipose tissue inflammation  
Adipose tissue was collected from C5 control (C5cont) and C5 deficient (C5def) mice 
after 12 weeks of LFD and HFD feeding and used for mRNA expression of: A) 
Emr1, B) Tnf, C) Il10, and D) Ccl2. Data are presented as mean ± SEM of 11-13 
mice per group, and were analyzed by two-way ANOVA with multiple comparisons.  
+ p<0.05; ++ p<0.01; +++ p<0.001 (diet effect) 
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Hepatic expression of Emr1, Tnf, and Il10 were not changed by diet or 
genotype (Figure 19A-C), while Ccl2 expression was increased in LFD-fed C5def 
mice (p<0.05, Figure 19D).  
 
Figure 19. Liver inflammation 
Liver was collected from C5 control (C5cont) and C5 deficient (C5def) mice after 12 
weeks of LFD and HFD feeding and used for mRNA expression of: A) Emr1, B) 
Tnf, C) Il10, and D) Ccl2. Data are presented as mean ± SEM of 11-13 mice per 
group, and were analyzed by two-way ANOVA with multiple comparisons.  
* p<0.05 (genotype effect) 
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AT sections were stained for F4/80 and analyzed by light microscopy. As 
expected, there was HFD-induced macrophage infiltration of AT; though, C5def 
mice had less HFD-induced crown-like structure formation than C5cont animals 
(Figure 20A, quantified in Figure 20B).  
 
 
Figure 20. Adipose tissue inflammation and physiology 
Adipose tissue (AT) was collected from C5 control (C5cont) and C5 deficient (C5def) 
mice after 12 weeks of LFD and HFD feeding and used for histological analyses. A) 
Fixed AT sections were stained with the macrophage marker F4/80. 
Representative images are shown are at 20X magnification. B) Quantification of 
crown-like structures per field-of-view (CLS/FOV). Data are presented as mean ± 
SEM from 3-4 mice per group, and were analyzed by two-way ANOVA with 
multiple comparisons. 
* p<0.05 (genotype effect) 
++ p<0.01 (diet effect) 
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Oil Red O staining of liver sections showed increased neutral lipid staining 
in HFD-fed compared to LFD-fed C5cont mice (Figure 21A). In contrast, HFD-
induced lipid accumulation was attenuated in the livers of C5def mice (Figure 
21A). Quantification of liver triglycerides confirmed these histological findings 
(Figure 21B). In fact, total triglyceride content was 70% lower in the C5def HFD 
group compared to the C5cont HFD group (p<0.001).  
 
Figure 21. Liver physiology 
Liver was collected from C5 control (C5cont) and C5 deficient (C5def) mice after 12 
weeks of LFD and HFD feeding and used for triglyceride quantification and 
histological analyses. A) Frozen liver sections were stained for neutral lipids using 
Oil Red O. Representative images are shown are at 10X magnification. B) 
Triglyceride content was quantified by GC-MS.  
Data are presented as mean ± SEM of 4-6 mice per group, and were analyzed by 
two-way ANOVA with multiple comparisons.  
*** p<0.001 (genotype effect) 
+++ p<0.001 (diet effect) 
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In support of decreased lipid content, liver expression of the enzyme acyl-
coenzyme A carboxylase was decreased in HFD-fed C5def mice when compared to 
the HFD-fed C5cont group (p<0.001; Figure 22A). Expression of other enzymes 
involved in hepatic glucose metabolism were not different between C5cont and C5def 
mice (Figure 22B-D). 
 
Figure 22. Hepatic glucose metabolism 
Liver was collected from C5 control (C5cont) and C5 deficient (C5def) mice after 12 
weeks of LFD and HFD feeding and used for mRNA expression of: A) Acyl-
coenzyme A carboxylase, B) Glucokinase, C) Glucose-6-phosphatase, and D) 
Phosphoenolpyruvate carboxykinase. Data are presented as mean ± SEM of 11-13 
mice per group, and were analyzed by two-way ANOVA with multiple comparisons.  
*** p<0.001 (genotype effect) 
+ p<0.05;++ p<0.01; ++++ p<0.0001 (diet effect) 
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C5def mice exhibit severe systemic glucose intolerance and IR 
 Data presented thus far shows that C5 deficiency has a relatively minimal 
effect on immune cell composition and inflammation in AT or liver, suggesting the 
altered metabolic phenotype in C5def mice is not immune cell mediated in those 
tissues. To determine if C5 deficiency impacts systemic glucose handling, 
intraperitoneal glucose tolerance tests (GTTs) were performed after 6 and 12 weeks 
of LFD or HFD feeding (Figure 23A-B). As expected, HFD feeding caused glucose 
intolerance in C5cont mice, and also in C5def mice, despite their lower body, liver, 
and AT weights, which are typically associated with better glucose control. C5def 
mice on both LFD and HFD were significantly more glucose intolerant than their 
C5cont counterparts (p<0.05 on LFD, p<0.01 on HFD at 12 weeks, AUC). In fact, at 
the 12-week time-point, C5def mice on LFD had the same glucose clearance rate as 
C5cont mice on HFD (Figure 23B). Further indication of IR in C5def mice, plasma 
insulin levels were elevated compared to control mice after 6 weeks of HFD feeding 
(p<0.0001; Figure 23C), although they were no longer significantly different after 
12 weeks (Figure 23D). 
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Figure 23.  Glucose tolerance and fasting insulin 
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD or HFD 
for 6 (A, C) or 12 (B, D) weeks and assessed for glucose tolerance (A-B) and fasting 
plasma insulin concentrations (C-D). Data are presented as mean ± SEM from 9-14 
mice per group. Bar graphs were analyzed by two-way ANOVA with multiple 
comparisons. Curves were analyzed by two-way ANOVA with multiple 
comparisons and repeated measures.  
* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 (genotype effect) 
+ p<0.05; ++ p<0.01 (diet effect) 
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To more thoroughly assess the metabolic phenotype of C5def mice, 
hyperinsulinemic-clamps were performed using C5cont and C5def mice that had been 
maintained on a LFD for 6 weeks. In both groups, blood glucose levels were 
successfully clamped at ~130 mg/dL (Figure 24A). However, the glucose infusion 
rate necessary to maintain euglycemia was strikingly lower in the C5def compared 
to C5cont mice (10 mg/kg/min versus 50 mg/kg/min, respectively; p<0.0001; 
Figure 24B), confirming that the C5def mice present with severe systemic IR, even 
on LFD.  
 
Figure 24. Hyperinsulinemic-euglycemic clamps and glucose infusion 
rate 
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD for 6 
weeks. During the last week, mice underwent surgical implantation of jugular and 
carotid catheters. Hyperinsulinemic-euglycemic clamps were performed as 
described in the Methods section. A) Blood glucose was clamped at ~130 mg/dL in 
each group. B) Glucose infusion rate required to clamp glucose. Data are presented 
as mean ± SEM from 5 mice per group. Curves were analyzed by two-way ANOVA 
with multiple comparisons and repeated measures.  
**** p<0.0001 (genotype effect) 
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Circulating insulin but not c-peptide levels were elevated in C5def mice, both 
at baseline and during the clamp (p<0.01; Figure 25A-B), suggestive of impaired 
first pass insulin extraction, as opposed to a difference in endogenous insulin 
secretion during clamp.  
 
Figure 25. Hyperinsulinemic-euglycemic clamps, serum insulin and      
c-peptide 
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD for 6 
weeks. During the last week, mice underwent surgical implantation of jugular and 
carotid catheters. Hyperinsulinemic-euglycemic clamps were performed as 
described in the Methods section. A) Plasma insulin and B) c-peptide in basal and 
clamp periods. Data are presented as mean ± SEM from 5 mice per group, and 
were analyzed by two-way ANOVA with multiple comparisons.  
** p<0.01 (genotype effect) 
^^ p<0.01 (clamp effect) 
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Despite the elevated circulating insulin concentrations, glucose production 
from the liver (endoRa) was equally suppressed during the clamp in both groups 
(p<0.001 for C5cont, p<0.0001 for C5def; Figure 26A). As expected, there was a 
significant negative correlation between serum insulin levels and endoRa in the 
C5cont group (r2=0.5023, p<0.05, Figure 26B). However, this correlation was not 
present in the C5def group (r2=0.1270, p=0.31), and more importantly, this 
relationship was shifted to the right, indicating IR in the livers of C5def mice.  
 
Figure 26. Hyperinsulinemic-euglycemic clamps, EndoRa and 
EndoRa:Insulin ratio  
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD for 6 
weeks. During the last week, mice underwent surgical implantation of jugular and 
carotid catheters. Hyperinsulinemic-euglycemic clamps were performed as 
described in the Methods section. A) Hepatic glucose production (EndoRa) and B) 
relationship between plasma insulin and EndoRa during basal and clamp periods. 
Data are presented as mean ± SEM from 5 mice per group. Bar graphs was 
analyzed by two-way ANOVA with multiple comparisons, and EndoRa:Insulin was 
analyzed by linear regression. 
^^^ p<0.001; ^^^^ p<0.0001 (clamp effect) 
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In addition, tissue-specific glucose uptake in the AT, muscle 
(gastrocnemius, soleus, and vastus lateralis) and heart was lower in C5def compared 
to C5cont mice (p<0.001, p<0.01, p<0.01, p<0.05, p<0.0001, respectively), while 
glucose uptake in brain was not different between the genotypes (Figure 27).  
Figure 27. Hyperinsulinemic-euglycemic clamps and tissue glucose 
uptake 
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD for 6 
weeks. During the last week, mice underwent surgical implantation of jugular and 
carotid catheters. Hyperinsulinemic-euglycemic clamps were performed as 
described in the Methods section. Glucose uptake (Rg) in adipose tissue, brain, 
gastrocnemius, soleus, vastus lateralis, and heart. Data are presented as mean ± 
SEM from 5 mice per group, and were analyzed by student’s t test with multiple 
comparisons. 
* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 (genotype effect) 
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IR in C5def mice was not associated with increased cellular stress 
Based upon the surprising finding that C5def mice exhibit severe IR, we 
sought to determine the mechanism(s) underlying this metabolic defect. It has 
been reported in these mice that C5 is synthesized in hepatocytes, but is not 
secreted [126]. Therefore, it is possible that accumulation of C5 protein in 
hepatocytes could result in endoplasmic reticulum (ER) stress and/or oxidative 
stress, leading to the observed IR in the liver of C5def mice. Thus, several markers 
of ER and oxidative stress were evaluated in livers of C5cont and C5def mice by 
western blot analysis. The protein levels of BiP, p-JNK1/2, and SOD-2 did not 
differ between C5cont and C5def mice either on LFD or HFD (Figure 28). IRE-1α 
protein levels were actually slightly lower in the liver of C5def mice on HFD 
(p<0.05). Thus, increased liver ER or oxidative stress does not explain the IR 
observed in these mice.  
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Figure 28. Hepatic ER- and oxidative-stress markers 
Protein lysates were collected from liver of C5 control (C5cont) and C5 deficient 
(C5def) mice fed LFD or HFD for 12 weeks. Western blot analysis was conducted to 
measure the protein expression of IRE-1α, BiP, phospho-JNK, and SOD2 in A) LFD 
and B) HFD mice. β-actin was used as a protein loading control. Quantification 
data in bar graphs are presented as mean ± SEM of 8 mice per group, and were 
analyzed by student’s t test with multiple comparisons. 
** p<0.01  
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C5def mice have decreased levels of insulin receptor mRNA and protein 
To further investigate a mechanism for the severe inflammation-
independent IR in C5def mice, insulin receptor (INSR) gene expression (Insr) was 
measured in both liver and AT. C5def Insr expression was reduced by more than 
50% in both liver and AT (p<0.001; Figure 29A-B), independent of diet.  
 
Figure 29. Insulin receptor gene expression liver and adipose tissue of 
C5cont and C5def mice  
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD or HFD 
for 12 weeks. Liver (A) and AT (B) were collected and RNA was isolated for gene 
Insr expression analysis. Data are expressed as mean ± SEM of 12-13 mice per 
group, and were analyzed by two-way ANOVA with multiple comparisons.  
*** p<0.001; **** p<0.0001 (genotype effect) 
+ p<0.05 (diet effect) 
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Liver gene expression of other insulin related proteins was also evaluated. 
Gene expression of the insulin signaling adaptor molecular, Irs1, was slightly 
increased in C5def mice fed HFD compared to LFD (p<0.05; Figure 30A). 
However, there were no genotype-driven differences in insulin-like growth factor 
(Igf1), insulin-like growth factor 1 receptor (Igf1r), insulin-like growth factor-
binding protein 3 (Igfbp3), or insulin signaling adaptor molecules (Irs1 and Irs2) 
(Figure 30A-E).  
 
Figure 30. Insulin signaling gene expression in liver of C5cont and C5def 
mice  
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD or HFD 
for 12 weeks. Liver was collected and RNA was isolated for gene expression 
analysis of A) insulin signaling adaptor molecular 1 (Irs1), B) insulin-like growth 
factor (Igf1), C) insulin-like growth factor 1 receptor (Igf1r), D) insulin-like growth 
factor-binding protein 3 (Igfbp3), and E) insulin signaling adaptor molecule 2 
(Irs2). Data are expressed as mean ± SEM of 12-13 mice per group, and were 
analyzed by two-way ANOVA with multiple comparisons.  
+ p<0.05 (diet effect) 
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Western blot analysis demonstrated a striking 50-70% decrease in the 
mature form of the β subunit of INSR (INSR-β) in liver and AT of C5def LFD-fed 
mice (p<0.0001, p<0.01, respectively, Figure 31A-B).  
 
Figure 31. Insulin receptor protein levels in liver and adipose tissue of 
C5cont and C5def mice  
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD for 6 
weeks, and protein lysates were collected from liver and adipose tissue (AT). 
Protein expression was assessed by western blot analysis. β-actin was used as a 
protein loading control. INSR-β protein levels in liver (A) and AT (B), respectively.  
Data in bar graphs are shown as mean ± SEM from 8 mice per group, and were 
analyzed with student’s t test. Representative images are below each graph.  
** p<0.01 (genotype effect) 
**** p<0.0001 (genotype effect) 
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A downstream indicator of INSR signaling, Akt phosphorylation (pAkt) at 
serine 473 was increased in liver of C5cont LFD-fed mice after insulin bolus 
(p<0.0001, Figure 32A). The insulin-stimulated increase in pAkt was blunted in 
liver of C5def LFD-fed mice (p<0.001, Figure 32A). In AT, pAkt trended towards 
an increase upon insulin stimulation in C5cont mice, and this effect appeared 
blunted in C5def mice (Figure 32B). 
 
Figure 32. Insulin signaling in liver and adipose tissue of C5cont and 
C5def mice 
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD for 6 
weeks, and protein lysates were collected from liver and adipose tissue (AT). Mice 
were injected with saline or 1 U/kg insulin 15 min prior to being euthanized.  
Protein expression and phosphorylation levels was assessed by western blot 
analysis. β-actin was used as a protein loading control. Phospho-Akt levels relative 
to total total Akt in A) liver and B) AT, respectively. Data in bar graphs are shown 
as mean ± SEM from 4-6 mice per group, and were analyzed with two-way ANOVA 
with multiple comparisons. Representative images are below each graph.   
*** p<0.001 (genotype effect) 
$$$$ p<0.0001 (insulin effect) 
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Differential processing of the pro-INSR in C5def mice  
 Functional INSR is initially synthesized as a single polypeptide known as 
pro-insulin receptor (pro-INSR) [137], and subsequent processing results in a 
mature INSR with α and β subunits [138]. To determine if these mice had altered 
pro-INSR expression or processing, an antibody that recognizes both the mature 
INSR-β and the precursor form was used. In all tissues assessed (liver, AT, muscle, 
pancreas, and brain, Figure 33), a pro-INSR band of approximately 190 kDa was 
detected by Western blot analysis. Interestingly, in C5def mice, an additional pro-
INSR band at 180 kDa was abundantly expressed in addition to the standard 190 
kDa band.   
 
Figure 33. Improper processing of pro-INSR in C5def mice  
Western blot analysis of the precursor of INSR (pro-INSR) in adipose tissue, brain, 
liver, muscle, and pancreas of C5 control (C5cont) and C5 deficient (C5def) mice. The 
normal pro-INSR band size is 190kDa. β-actin was used as a protein loading 
control. 
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To determine if the pro-INSR processing error was specific to INSR in C5def 
mice, western blotting of several other endocytic recycling receptors was 
performed. There were no differences in the molecular weight of the low density 
lipoprotein receptor (LDLR), epidermal growth factor receptor (EGFR), or 
transferrin receptor (Tfr1) in liver of the C5cont and C5def mice (Figure 34). Thus, 
the processing defect in C5def mice appears to be specific to the INSR. 
 
Figure 34. Western blot analysis of endocytic recycling receptors 
Western blot analysis of low density lipoprotein receptor (LDLR), epidermal 
growth factor receptor (EGFR), or transferrin receptor (Tfr1) in liver of the C5 
control (C5cont) and C5 deficient (C5def) mice. β-actin was used as a protein loading 
control. 
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Phenotype of C5cont and C5def mice is conserved in females 
 Female C5def mice were evaluated for their metabolic phenotype. When put 
on HFD for 6 weeks, C5cont mice gained more weight than C5def (Figure 35A). The 
C5def on HFD displayed a slight decrease in lean mass compared to C5cont (Figure 
35B), but no statistically significant differences in AT mass (Figure 35C). 
Importantly, similar to the males (Figure 23A), C5def mice on LFD had impaired 
glucose tolerance (p<0.01, AUC) that was exacerbated on HFD (p<0.001, AUC, 
Figure 35D). The liver of female C5def animals also displayed reduced INSR-β 
expression and presence of the pro-INSR double band (Figure 35E).  
 
Figure 35. Metabolic parameters of female C5cont and C5def mice  
Female C5 control (C5cont) and C5 deficient (C5def) mice were placed on LFD or 
HFD for 6 weeks. A) Body weight. B) Total lean mass and C) total adipose tissue 
mass as measured by NMR. D) Glucose tolerance test. E) Western blot analysis of 
liver pro-INSR and INSR-β. β-actin was used as a protein loading control. Data are 
presented as mean ± SEM of 3-4 mice per group, and were analyzed by two-way 
ANOVA with multiple comparisons, with repeating measures for GTT.  
* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 (genotype effect) 
+ p<0.05 (diet effect) 
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Phenotype of C5 heterozygous mice 
 C5cont female and C5def male mice were bred to generate C5 heterozygous 
(C5het) mice. Male mice of each genotype were fed HFD for 6 weeks, after which 
there were no observed differences in body weight, lean mass, or AT mass between 
groups (Figure 36A-C). Glucose tolerance tests revealed that C5het mice had the 
same degree of glucose intolerance as C5def mice (p<0.05, AUC, Figure 36D). The 
liver of C5het mice displayed reduced expression of INSR-β and the pro-INSR 
double band, similar to the C5def (Figure 36E).   
 
Figure 36. Metabolic parameters of C5het mice  
C5 control (C5cont), C5 heterozygous (C5het), and C5 deficient (C5def) mice were 
placed on HFD for 6 weeks. A) Body weight. B) Total lean mass as measured by 
NMR C) Total adipose tissue mass as measured by NMR. D) Glucose tolerance test. 
E) Western blot analysis of pro-INSR and INSR-β from liver of C5cont, C5het, and 
C5def mice. β-actin was used as a protein loading control. Data are presented as 
mean ± SEM of 4-5 mice per group, and were analyzed by two-way ANOVA with 
multiple comparisons, with repeating measures for GTT. 
*,# p<0.05; **,##  p<0.01; ***, ### p<0.001 
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Pro-INSR processing is not disrupted in other C5 deficient mouse models 
The C5def Jackson Laboratory mouse characterized in these studies (B10.D2-
Hc0H2dH2-T18c/oSnJ) is one of several known mouse models deficient for C5. To 
rigorously assess the impact of C5 deficiency on INSR processing, seven other C5 
deficient mouse models were obtained from Jackson Laboratory in order to 
determine whether mis-processed pro-INSR was present in all C5 deficient models. 
Western blot analysis was used to evaluate the INSR in livers from the mice. 
Surprisingly, none of the other C5 deficient models displayed the misprocessed 
pro-INSR or decreased INSR-β protein (Figure 37). Two of these mouse lines, 
AKR/J and DBA/2J (designated with * in the figure), have the same 2 base-pair 
deletion as the C5def mouse in these studies, but did not show any changes in INSR 
protein compared to C57BL/6J wildtype or C5cont mice.  
 
Figure 37. Pro-INSR processing in other C5 deficient mouse models 
Western blot analysis of pro-INSR and INSR-β from liver of C57BL/6J, C5cont, 
C5def, AKR/J, DBA/2J, A/J, CBA/J, DBA/1J, FVB/NJ, and NOD/ShiLtJ mice. β-
actin was used as a protein loading control. * denotes the same 2 base-pair deletion 
as C5def. 
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Genetic analysis of the insulin receptor gene in C5cont and C5def mice 
With the novel information that C5 deficiency alone cannot account for the 
metabolic phenotype of the C5def mice, whole genome sequencing was performed 
to determine whether there is a genetic basis for the INSR processing phenotype. 
Genomic DNA was isolated from liver of C5cont and C5def mice and sequenced. The 
2-base pair mutation in Exon 6 of the C5 gene in C5def was confirmed (Figure 38). 
Next, the Insr gene was analyzed for genetic variation. While there were no 
differences observed in the exons, we discovered a 31 base-pair deletion in the 
intronic region just upstream of Exon 2 (Figure 39).  
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Figure 38. Genetic analysis of the Hc gene in C5cont and C5def mice 
Integrative Genomics Viewer (IGV) screenshots from the Hc (C5) gene sequences 
across reads from FASTQ files generated by whole genome sequencing of C5 
control (C5cont) and C5 deficient (C5def) murine liver. The top image shows a 
representative C5cont sample, and the bottom shows a representative C5def sample. 
The yellow rectangular shading denotes the location of the 2 base-pair deletion in 
Exon 6 of Hc in C5def mice. Other shading is a reflection of read attributes within 
the IGV software. Data are representative of 3 per group.  
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Figure 39. Genetic analysis of the insulin receptor gene in C5cont and 
C5def mice 
Integrative Genomics Viewer (IGV) screenshots from the Insr gene sequences 
across reads from FASTQ files generated by whole genome sequencing of C5 
control (C5cont) and C5 deficient (C5def) murine liver. The images on the left side 
show n=3 C5cont samples, and n=3 C5def samples on the right. The yellow 
rectangular shading denotes the location of the 31 base-pair deletion in an intronic 
region of the Insr gene in C5def mice. Other shading is a reflection of read attributes 
within the IGV software.  
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Forced C5 expression enhances glucose homeostasis and insulin sensitivity  
 To determine the contribution of INSR insufficiency versus C5 deficiency to 
the IR noted in C5def mice, we provided exogenous human C5 by systemic 
adenoviral (Ad) transfection. LFD-fed C5cont and C5def mice received an injection of 
either control (AdGFP) or human C5 (AdC5) adenovirus. During a 
hyperinsulinemic-euglycemic clamp, blood glucose concentrations were 
appropriately clamped so there were no differences between AdGFP and AdC5-
treated mice regardless of genotype (Figure 40A-B). Adenoviral delivery of C5 
increased the glucose infusion rate required to maintain euglycemia in both C5cont 
mice (p<0.01, Figure 40C) and C5def animals (p<0.001, Figure 40D).  
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Figure 40. In vivo C5 delivery and insulin sensitivity via 
hyperinsulinemic-euglycemic clamp 
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD for 14-16 
weeks and received a single injection of adenoviral vector for control (AdGFP) or 
C5 (AdC5) four weeks prior to hyperinsulinemic-euglycemic clamps. A-B) Arterial 
blood glucose and C-D) glucose infusion rate during a hyperinsulinemic-
euglycemic clamp. Data are presented as mean ± SEM of 5-7 mice per group. 
Curves were analyzed by two-way ANOVA with multiple comparisons and repeated 
measures.  
@@ p<0.01; @@@@ p<0.0001 (AdC5 effect) 
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 Basal insulin concentrations were higher in C5def compared to C5cont mice as 
expected (Figure 41B vs. 41A), but were not affected by AdC5 treatment in either 
genotype. During the clamp, plasma insulin levels trended toward a decrease in 
AdC5 compared to AdGFP in both genotypes (C5cont; p=0.08, Figure 41A) and 
(C5def; p=0.07, Figure 41B). Relative to basal conditions, administration of AdC5 
to C5cont mice attenuated insulin suppression of endoRa (Figure 41C). In contrast, 
AdC5 administration to C5def mice did not impair insulin suppression of endoRa 
(p<0.01, Figure 41D). The rate of glucose disappearance during the clamp was 
heightened in C5def+AdC5 mice, while C5cont+AdC5 animals showed a non-
significant increase (Figure 41E-F).  
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Figure 41. In vivo C5 delivery and insulin sensitivity via 
hyperinsulinemic-euglycemic clamp 
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD for 14-16 
weeks and received a single injection of adenoviral vector for control (AdGFP) or 
C5 (AdC5) four weeks prior to hyperinsulinemic-euglycemic clamps. Basal and 
clamp period A-B) plasma insulin, C-D) endoRa, and E-F) and whole body glucose 
disappearance Rd. Data are presented as mean ± SEM of 5-7 mice per group, and 
were analyzed by two-way ANOVA with multiple comparisons.  
@@ p<0.01 (AdC5 effect) 
^ p<0.05; ^^ p<0.01; ^^^ p<0.001; ^^^^ p<0.0001 (clamp effect) 
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 Relative to respective AdGFP controls, C5cont+AdC5 and C5def+AdC5 
animals showed increased glucose uptake specifically in BAT (p<0.05, Figure 
42A-B); whereas, glucose disposal in the heart was also increased in C5def+AdC5 
mice (p<0.05, Figure 42B).  
 
Figure 42. In vivo C5 delivery and insulin sensitivity via 
hyperinsulinemic-euglycemic clamp 
C5 control (C5cont) and C5 deficient (C5def) mice were maintained on LFD for 14-16 
weeks and received a single injection of adenoviral vector for control (AdGFP) or 
C5 (AdC5) four weeks prior to hyperinsulinemic-euglycemic clamps. A-B) Tissue 
specific glucose (Rg) uptake during clamp. Data are presented as mean ± SEM of 5-
7 mice per group, and were analyzed by student’s t test with multiple comparisons. 
@ p<0.05; @@ p<0.01 (AdC5 effect) 
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 Together, these findings indicate that the IR in the C5def B10.D2-Hc0 H2d 
H2-T18c/oSnJ mice is indeed driven by the INSR mutation, and also show that 
forced expression of C5 improves insulin sensitivity irrespective of whether 
endogenous C5 is present and even on a background of extreme IR.  
 
  
! 72 
Discussion 
Our studies aimed to elucidate the role of C5 in metabolic disease by 
utilizing the Jackson Laboratory C5def mouse, but have instead revealed a novel 
metabolic phenotype of the C5def B10.D2-Hc0 H2d H2-T18c/oSnJ strain that may 
be caused by a genetic alteration in the Insr gene. While unexpected, these results 
expose a novel mouse model for studying IR, and provide a previously unreported 
phenotype of the Jackson Laboratory C5def mouse with implications for other 
investigations that have utilized this model. Although the IR phenotype of the C5def 
model was driven by the Insr mutation, adenoviral delivery of human C5 improved 
insulin action in lean C5cont and C5def mice, suggesting that C5 does indeed have 
insulin sensitizing actions. Further work, beyond the scope of this study, will need 
to be performed to validate this observation. 
C5def mice display an obesity- and inflammation-independent insulin 
resistant phenotype. Notwithstanding the lack of inflammation, C5def mice 
manifest severe IR characterized by glucose intolerance, hyperinsulinemia, and 
blunted insulin-mediated glucose disposal. These disturbances in glucose 
metabolism occur regardless of obesity, such that C5def mice fed a LFD display the 
same degree of glucose intolerance as HFD-fed C5cont animals.  This remarkable 
degree of IR in C5def mice phenocopy several different tissue-specific INSR 
knockout mice, but unlike global INSR knockout mouse models, these mice are 
viable. For example, the dwarfing phenotype mimics disrupted INSR signaling 
during development, where the INSR is required for IGF-2 signaling to promote 
lean mass growth [139]. Additionally, the ~30% reduction in total fat mass and 
~70% reduction in liver triglycerides are consistent with deficient INSR signaling 
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in AT and liver, as similar phenotypes were observed in mice with fat and liver-
specific INSR deficiency [140, 141].  
Several parameters were tested to determine a mechanism for the observed 
systemic IR of C5def mice. While ER and oxidative stress was unaffected in the liver, 
insulin-stimulated, AKT phosphorylation was impaired in liver and AT of C5def 
mice (Figure 23). Interestingly we did not detect impaired Akt signaling in 
skeletal muscle of the C5def mice. This result is similar to that obtained for the 
muscle-specific Insr knockout mouse where signaling downstream of IGF-1R was 
shown to play an important compensatory role in muscle [142]. Differential 
processing of pro-INSR was observed in metabolic tissues of the C5def mice 
(Figure 33). Further studies are needed to characterize the structure of the 
observed 180kDa pro-INSR translation product, and this is discussed in more 
detail in Chapter 4 of this Dissertation. Thus, we have shown that C5def mice have 
impaired INSR processing, decreased INSR mRNA and protein expression, and 
blunted INSR signaling, likely accounting for the observed glucose intolerance and 
severe systemic IR in this model. 
The phenotype of the C5het mice (Figure 36) also presents potentially 
interesting genetics associated with the C5def mice. The glucose intolerance of the 
C5het mice mirrored that of the C5def, suggesting a dominant negative expression 
pattern. Leprechaunism and Rabson-Mendenhall syndrome and other inherited 
forms of IR are difficult to diagnose, but human studies have characterized many 
associated mutations [143-147]. Often, these mutations occur in the tyrosine kinase 
domain of the protein and act dominantly, possibly by forming hybrid dimers [145, 
147] or by sequestering IRS-1 substrate [148]. The only mutation we detected in the 
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INSR of the C5def B10.D2-Hc0 H2d H2-T18c/oSnJ mice was in an intronic region, 
leading to a truncated protein. The mechanism by which this truncation causes IR 
in a dominant negative fashion is an area of future investigation as it may prove to 
be relevant to human disease as well, and is discussed further in Chapter 4 of this 
Dissertation. 
With the elucidation of the extreme IR in the Jackson Laboratory B10.D2-
Hc0H2dH2-T18c/oSnJ C5def mice, it is important to recognize that these mice have 
been used extensively in many fields of study – fields in which IR could influence 
disease outcomes. As expected, C5def mice have been used in studies of bacteriology 
and pathogenesis, but it is now appreciated that IR in humans is associated with a 
higher incidence of infection and associated complications, especially in diabetic 
patients [149, 150]. In addition to the inflammation-specific applications of this 
mouse model, it has also been used to investigate the role of C5 in areas less 
traditionally associated with innate immunity. For example, Ehrnthaller et al. 
studied the role of complement in fracture healing by evaluating C3-/- and C5def 
mice. They reported that C5 is required for proper healing [151], but it is well 
known that diabetic subjects are at higher risk for bone fracture, and that their 
healing processes are impaired [152]. Additionally, Pasinetti et al. reported that C5 
influences glutamatergic neurotransmission and neurodegenerative disease [153], 
but it has also been shown that diabetes influences the genetic basis of 
glutamatergic signaling [154]. Thus, the insulin resistant phenotype of the C5def 
mice may introduce variables that were not previously appreciated in 
investigations that have used this mouse line. 
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 Although mutation of the INSR in the C5def mice likely accounts for the 
insulin resistant phenotype, our studies reveal that adenoviral delivery of C5 
enhances insulin sensitivity and improves glucose homeostasis. This notable 
finding indicates that C5 is an important regulator of metabolic function that is not 
fundamentally linked to insulin signaling. Interestingly, as early as 1979 it was 
discovered that C5a can induce the uptake of deoxyglucose in neutrophils by as 
much as 700% [103]. The authors suggested that upon activation of complement, 
immune cells require a burst of energy and thus, the cells must have a way to 
regulate their glucose uptake. Because neutrophils don’t upregulate glucose uptake 
in response to insulin, the authors put forth the titillating hypothesis that “C5a 
might have developed phylogenetically as an ‘insulin’ for phagocytes [103].” A 
similar induction of glucose uptake in eosinophils has also been reported [104], 
and it was published that C5a and C3a have insulin-like effects on 3T3-L1 
adipocytes [155]. Thus, our in vivo adenoviral studies extend what has previously 
been shown in vitro and reinvigorates the novel idea that C5 has beneficial effects 
on metabolic homeostasis. 
 
Conclusions 
It is now well-established that the inflammatory state of the AT and other 
metabolic organs is an important determinant of disease phenotypes associated 
with the onset and progression of obesity. The complement system is intricately 
involved in inflammation and associated metabolic disease, but C5 specifically has 
also been shown to have metabolically beneficial effects by promoting glucose 
uptake. These connections, as well as our data showing increased Hc expression in 
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diet-induced obese mice, led to the experiments shown here asking how C5 
deficiency influences metabolism. Our data show that the B10.D2-Hc0H2dH2-
T18c/oSnJ C5def mouse is severely insulin resistant, which is also associated with 
misprocessing of the INSR precursor, pro-INSR, due to a genetic deletion in an 
intronic region of the Insr gene. Furthermore, we show for the first time that 
forced expression of C5 improves insulin sensitivity, presenting an opportunity to 
further investigate the therapeutic potential of C5 on insulin action and glucose 
homeostasis.  
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CHAPTER 4 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
The immunophenotype of brown adipose tissue  
 It is well-appreciated that immune cells and the cytokines they secrete and 
signal through contribute to WAT homeostasis, and that this microenvironment 
changes with the onset and progression of obesity. In contrast to the lipid storage 
role of WAT, BAT can burn lipid through thermogenesis. These AT depots have 
very different functions, and as such, our data presented in Chapter 2 are not 
particularly surprising in highlighting not only the very low numbers of immune 
cells in BAT, but also the obesity-driven changes that do not align with WAT 
literature. There have not been many studies that characterize BAT immune cells 
since the publication of my manuscript detailed in Chapter 2. A review article from 
2018 [156] summarized the field’s knowledge of immune cells in BAT by describing 
changes in cytokine gene expression rather than actual cell numbers, as we 
performed in [89]. There is evidence that brown adipocytes are also capable of 
secreting cytokines such as TNF-α and IL-6 [157], so gene expression alone is not 
an appropriate method by which cell population discoveries are made. Since my 
study, flow cytometry has not been used to characterize the BAT SVF; however, 
there have been advances for its use in adipocyte studies [158, 159]. These methods 
will be helpful for future studies in this field because it will allow for more detailed 
analysis of AT cells, regardless of depot. Historically, adipocytes have been 
separated from the SVF by buoyancy, and the entire floating fraction is evaluated 
as one entity. Histological studies have shown that AT does not necessarily change 
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in a uniform way with disease onset and progression though, so it will be 
interesting to have a molecular tool to further evaluate adipocytes in ways similar 
to the SVF. Furthermore, histology of beiged AT also shows a spectrum of changes 
over time of treatment (i.e. cold exposure), and these studies will benefit from 
more advanced adipocyte characterization.  
 Concomitantly with the field’s shift of focus to the adipocytes in BAT and 
beige AT is a shift in the literature discussing the role of immune cells in 
thermogenesis. One paper that sparked the studies presented in Chapter 2 showed 
alternatively activated macrophages as producers of catecholamines that can 
activate thermogenesis [96]. This discovery was had vast implications because 
macrophages are so intricately involved with AT homeostasis. One may propose 
that these macrophages could be targeted to produce norepinephrine locally in 
order to initiate thermogenesis. Unfortunately, these findings have since been 
disputed and the alternative findings were published not long before our article in 
Obesity (Chapter 2) [93]. Hence, the focus in the field has since returned to 
understanding the different types of adipocytes and how to therapeutically alter 
their phenotype, potentially in UCP1-independent ways [160].  
 
The role of complement in metabolism  
 The studies presented in Chapter 3 showed that the Jackson Laboratory 
B10.D2-Hc0 H2d H2-T18c/oSnJ C5def mice are severely insulin resistant, but this is 
attributed to an INSR defect, rather than C5 deficiency alone. This was an 
unexpected finding that has made the necessity of a novel mouse model of C5 
deficiency obvious, but there are still further investigations necessary in the C5def 
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mice. Namely, the Pro-INSR misprocessing and INSR genetics of the C5def mice 
may be applicable to IR research in general. It is also of upmost importance to ask 
our original question about the role of C5 deficiency in metabolism using a model 
that does not have these confounding factors. This will allow for further 
mechanistic analyses about the role of C5 and other complement proteins in the 
realm of metabolism.  Each of these areas will be discussed in detail below.  
 
Pro-INSR is misprocessed in C5def mice 
 Metabolic tissues from C5def mice exhibit a second band of lower molecular 
weight for the INSR translation product, Pro-INSR, when analyzed by western blot 
(Figure 33). Such data typically indicates two versions of the protein that have 
been processed differently during protein maturation. Posttranslational processing 
occurs in the endoplasmic reticulum and/or Golgi. Typically, if a protein is not 
properly glycosylated, the consequence is decreased mature receptor at the 
membrane because of improper protein folding, as seen in Figure 31.  
In preliminary work, a PNGase F assay was used to determine whether there 
were differences in N-linked glycosylation between the normal single band in C5cont 
animals and the lower band from C5def (Figure 43). PNGase F removes N-linked 
glycosylation from the protein, so if different degrees of glycosylation are the 
difference between the two bands, both bands should shift lower to become one 
single non-glycosylated Pro-INSR. In contrast, the data show that both C5def bands 
migrate, confirming that N-linked glycans were removed, but two distinct bands 
remained, indicating additional modifications exist between the bands. 
Additionally, the active subunit of INSR, INSR-β, also showed a double band in 
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C5def samples after PNGase F treatment. Further studies to uncover the differences 
between the bands could utilize mass spectrometry, but protein purity may be 
problematic without different antibodies specific to each band.  
 
Figure 43. Glycosylation analysis by PNGase F assay  
Western blot analysis of liver from C5 control (C5cont) and C5 deficient (C5def) 
treated with (+) and without (-) F-glycosidase (PNGase F) treatment to remove N-
linked glycosylation. Pro-INSR and INSR-β are indicated, and β-actin was used as a 
loading control.  
 
Nonetheless, these data show that C5cont and C5def Pro-INSR have differential 
N-linked glycosylation, as well as other modifications. Such modifications may 
include addition of fatty acids by amide or ester linkages [161]. Because the C5def 
mice present with such a remarkable alteration in posttranslational processing of 
InsR, we expect that this would also lead to altered expression at the cell surface, 
which could be measured by biotinylation or radioligand binding assays. This is 
interesting as it has been shown that mice with a tissue specific deletion of InsR in 
liver [141], pancreas [162], and brain [163] exhibit phenotypes that mirror our C5def 
mice including elevated plasma insulin levels and IR. Given the improper InsR 
processing that occurred in the tissues of C5def mice, it is not surprising that they 
Pro$InsR)
InsR$β)
β$ac-n)
C5cont)) C5def)
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have a metabolic phenotype similar to various tissue specific InsR knockout 
models.  
 
Genetic defect in the insulin receptor gene of C5def mice 
 Whole genome sequencing analysis of liver from C5cont and C5def mice 
revealed an intronic 31 base pair deletion in the Insr gene of the C5def animals 
(Figure 39). While this particular defect has not been previously reported, there 
are many known Insr mutations in humans with T2D or severe inherited IR [143, 
164-170]. Most of the known mutations occur in the portion of the gene that codes 
for the tyrosine kinase domain, exons 17-21 (Figure 44), but some have also been 
shown in intronic regions throughout the gene [171-173]. The relative location of 
our discovered deletion in the intronic region near exon 2 is indicated in Figure 44 
with a red arrow. 
 
Figure 44. Insr gene map 
Adapted from Olefsky, Diabetes (1990) [174] 
The 22 exons and their functional protein domains in the insulin receptor (Insr) 
gene are shown as labeled. The red arrow indicates the relative location of the 
intronic 31 base pair deletion we discovered in C5 deficient (C5def) mice.  
 
 Alternative splicing is known to occur in the Insr gene, most notably via 
excision of exon 11 to form two INSR isoforms with variable insulin action and 
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function [175-177]. Because the C5def Insr deletion was in the intronic region 
between exons 1 and 2, we aimed to determine whether this led to a splicing event 
that affected the flanking exons. Primers were designed to amplify these exons by 
polymerase chain reaction (PCR) so that we could determine whether transcription 
was affected. The data show an expected decrease in mRNA expression in the C5def 
exons (similar to Figure 29), but do not show band size differences between C5cont 
and C5def (Figure 45). This indicates that the Insr mutation did not alter exons 1 
or 2 at the transcriptional level. It is possible that other areas of the gene may be 
affected, but further analysis by PCR and/or Northern Blot would be required.  
 
Figure 45. Gel electrophoresis of Insr exons 1 and 2 
mRNA from liver of C5 control (C5cont) and C5 deficient (C5def) mice was isolated 
and reverse transcribed to cDNA. Polymerase chain reaction was used to amplify 
exons 1 and 2 from the Insr gene via gel electrophoresis on a 1% agarose gel 
visualized by ethidium bromide.  
 
 Interestingly, several N-linked glycosylation sites are located in the INSR α-
subunit that is coded for in exon 2 [178]. While the mutation in C5def mice may not 
affect splicing or transcription, it is possible that the deletion affects nearby 
glycosylation, which could also explain the Pro-INSR double band observed in 
Figure 33. Further in vitro and biochemical analyses are necessary fully 
understand the consequence of the Insr mutation observed in C5def mice.   
Exon%1%
Exon%2%
C5cont% C5def%
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Utilization of CRISPR technology for a novel mouse model of C5 deficiency 
 With the knowledge that the Jackson Laboratory C5def mouse also has a 31 
base pair deletion in an intronic region of the INSR gene, it is necessary to ask how 
C5 deficiency influences systemic metabolism in a cleaner mouse model. 
Accordingly, we worked with the Vanderbilt Genome Editing Resource to utilize 
CRISPR-Cas9 editing technology to generate an Hc (C5) knockout mouse via 
deletion of Exon 3 from C57BL/6J mice. Upon injection of 92 embryos, 76 
implanted, and 11 live births occurred. Four mice (1 female, 3 males) had the 
deletion of Exon 3 and are currently being bred with C57BL/6J wildtype animals to 
expand the colony for evaluation. In caution of off-target effects from the CRISPR-
Cas9 system, each knockout animal’s colony will be kept separate until initial 
characterization. Although unlikely, if there are differences in phenotypes between 
the knockout lines, this will provide evidence of off-target effects and genetic 
variation outside of the Hc gene.  
 
Mechanisms by which C5 improves insulin action 
 While the INSR defect in the C5def mice certainly confounded the questions 
addressed in Chapter 3, adenoviral delivery of C5 improved insulin sensitivity in 
both the insulin resistant C5def and healthy C5cont mice (Figures 40-42). These 
data show metabolically beneficial effects of C5, and lead us to hypothesize that the 
Hc (C5) CRISPR-Cas9 knockout mice will have worsened systemic metabolism 
than controls. There are other hints in the literature that support this premise as 
well. For example, and as mentioned in the Discussion of Chapter 3, C5 has been 
shown to induce glucose uptake. Delving deeper into a potential mechanism 
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behind these effects requires a closer look at the C5 signaling pathway          
(Figure 46).  
 
C5 receptors and metabolism  
 There are two known receptors for C5a, C5aR1 and C5aR2 (also called 
C5L2). Both are expressed on many immune [179] and non-immune cells, 
including adipocytes and hepatocytes [180]. C5aR1 was discovered in 1991 as a Gαi 
or Gα16-coupling GPCR with high binding affinity to C5a [181-186]. In contrast, 
C5aR2 has been shown to bind C3a, C3adesArg, C5a, and C5adesArg, with highest 
affinity to the latter two [187, 188]. Like C5aR1, C5aR2 is a seven-transmembrane 
receptor, but studies suggest that binding does not lead to G-protein coupling, and 
it has been thought to be a decoy receptor for C5aR1 [187-189].  
 
Figure 46. C5 signaling pathway 
 
C3, C3aR, C5aR1, and C5aR2 knockout mice have been generated and 
evaluated for their metabolic phenotype. As expected, C3aR and C5aR1 knockout 
mice show decreased inflammation and protection against IR [107, 190], 
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presumably due to dampened inflammatory responses. In contrast, both C3-/- and 
C5aR2-/- have a phenotype of elevated plasma insulin and decreased glucose 
tolerance [191-193]. Given that C3-/- mice also lack C3a, C3adesArg, C5a, C5b, and 
C5adesArg, the results obtained in these two models could be a consequence of 
absence of signaling through C5aR2. Interestingly, studies also show that 
polymorphisms in C5aR2 are associated with T2D in humans [194], suggesting an 
important role for C5aR2 in metabolism.  
In addition to what is known about C5’s ability to influence glucose uptake, 
HEK cells made to over-express C5aR2 have enhanced glucose uptake in response 
to C3adesArg [195] and antibody neutralization of C5aR2 has been shown to increase 
blood glucose levels after a fat load (indicating reduced glucose uptake) [102]. In 
fact, most of the work on complement and adipose-related metabolism has been on 
C3adesArg (also called acylation stimulating protein, ASP), showing its role in 
glucose uptake [196, 197], TG synthesis [198, 199], adipocyte differentiation [200], 
postprandial TG clearance [201], and insulin secretion [202]. Recent evidence also 
suggests that in response to C3adesArg, C5aR2 can be phosphorylated, and 
subsequently signal through Akt and ERK1/2, leading to glucose uptake and TG 
synthesis [195, 203]. 
Thus, the current literature shows that C5a or C3adesArg treatment stimulates 
glucose uptake in a way similar to insulin action on metabolic cells, and that the 
receptor for these mediators, C5aR2, is necessary for proper metabolic action in 
vivo. The studies presented in Chapter 3 show that adenoviral delivery of C5 
improves insulin action (Figures 40-42). Based on these observations, we 
propose the novel hypothesis that C5a mediates inflammatory effects via C5aR1 
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while C5adesArg mediates metabolic benefits via C5aR2 (Figure 45). Future 
studies will test this hypothesis by administration of C5adesArg in the Hc (C5) 
knockout CRISPR-Cas9 mice to determine if this assumed inactive protein can 
improve insulin sensitivity in vivo. Furthermore, in vitro studies can be utilized to 
isolate parts of the C5 signaling pathway and determine whether C3adesArg and/or 
C5adesArg signaling specifically via C5aR2 leads to the metabolic effects.  
 
Conclusion 
 This Dissertation details my contributions to the field of 
Immunometabolism, specifically in the areas of BAT immune cells and the role of 
C5 in insulin action. I discovered B cells in BAT and showed that the numbers of 
these cells, as well as macrophages and eosinophils, change in change in response 
to HFD-induced obesity, but not during aging (Chapter 2). I also revealed that the 
Jackson Laboratory mouse model of C5 deficiency has a phenotype of severe IR 
that may be attributed to a genetic variant in the Insr gene. Additionally, 
adenoviral C5 delivery showed that C5 has beneficial effects on systemic insulin 
action (Chapter 3). Many questions remain in these areas, and it will be interesting 
to see where the trajectory of these studies goes next. 
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APPENDIX 
 
MACROPHAGE-TARGETED THERAPEUTICS FOR METABOLIC DISEASE 
This Appendix were adapted from  
a review article published in Trends in Pharmacological Sciences titled,  
Macrophage-Targeted Therapeutics for Metabolic Disease 
written by Peterson, Cottam, Kennedy, and Hasty [204], 
 
Abstract 
Macrophages are cells of the innate immune system that are resident in all tissues, 
including metabolic organs such as the liver and adipose tissue. Because of their 
phenotypic flexibility, they play beneficial roles in tissue homeostasis, but they also 
contribute to the progression of metabolic disease. Thus, they are ideal therapeutic 
targets for diseases such as insulin resistance, non-alcoholic fatty liver disease, and 
atherosclerosis. Recently, discoveries in the area of drug delivery have facilitated 
phenotype-specific targeting of macrophages. In this review, we discuss advances 
in potential therapeutics for metabolic diseases via macrophage-specific delivery. 
We highlight micro- and nano-particles, liposomes, and oligopeptide complexes, 
and how they can be used to alter macrophage phenotype for a more metabolically 
favorable tissue environment.  
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Glossary 
 
ATM (Adipose tissue macrophage): Macrophages in the adipose tissue. 
 
CD163: A high affinity scavenger receptor for the hemoglobin-haptoglobin 
complex used to identify an M2-polarized macrophage marker. 
 
CCL2, CCL3, and CCL5 (Chemokine (C-C motif) ligands 2, 3, and 5, 
respectively): Cytokine ligands involved in the recruitment of leukocytes. 
 
CRISPR-Cas9: Bacterial-based immune defense that leads to destruction of 
specific genetic sequences. This can be delivered and utilized in other systems to 
silence target genes of interest.  
 
GeRPs (β1,3-d-glucan-encapsulated siRNA particles): Yeast-derived glucan shells 
that encapsulate macrophage-targeted siRNA.  
 
iNOS2 (Inducible nitric oxide synthase 2): An enzyme that produces reactive free 
radicals of nitric oxide when induced by a combination of cytokines and 
lipopolysaccharide.  
 
IR (Insulin resistance): A condition in which cellular response to the hormone 
insulin is reduced, leading to dysfunctional glucose homeostasis. 
  
IL-1β (Interleukin 1 beta): Pro-inflammatory cytokine produced by activated 
macrophages. 
 
IL-4 (Interleukin 4): Anti-inflammatory cytokine produced by T cells that 
promotes alternative activation and inhibits classical activation of macrophages. 
 
IL-6 (Interleukin 6): Pro-inflammatory cytokine produced by T cells and 
macrophages that stimulates an immune response. 
 
IL-13 (Interleukin 13): Anti-inflammatory cytokine produced by T cells, basophils, 
and eosinophils that promotes alternative activation of macrophages. 
 
IL-33 (Interleukin 33): Anti-inflammatory cytokine produced by macrophages and 
dendritic cells that drives production of other anti-inflammatory cytokines, 
including IL-4 and IL-13 by T cells. 
 
Kupffer cells: Macrophages that are resident in the liver. 
 
M1-like macrophage: Classically activated macrophage with a pro-inflammatory 
phenotype most often associated with host defense. 
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M2-like macrophage: Alternatively activated macrophage with an anti-
inflammatory and pro-fibrogenic phenotype most often associated with tissue 
repair. 
 
MMe (Metabolically active macrophages): Macrophages that are activated by 
metabolic growth factors and are resident to adipose tissue. They produce pro-
inflammatory cytokines, but express markers that are more similar to M2-like 
macrophages, including ABCA1, CD36, and PLIN2. 
 
MFehi: ATMs with high iron content that can recycle iron and display a M2-like 
phenotype. 
 
M(Hb): Macrophages with unique phenotype resulting from uptake of 
haptoglobin-hemoglobin complexes. 
 
Mhem: Macrophages with unique phenotype resulting from uptake of heme. 
 
NAFLD (Non-alcoholic fatty liver disease): A class of liver disease characterized by 
fat deposition in the liver that is not associated with alcohol consumption. 
 
ROS (Reactive oxygen species): Oxygen containing chemical species that are 
produced by cells at high levels in response to pathogens or inflammatory stimuli.  
 
siRNA (Small interfering RNA): Gene silencing technology that interferes with 
transcription of genes. 
 
SPIONs (Superparamagnetic iron oxide nanoparticles): Engineered tool that 
targets macrophages and was originally used for imaging techniques, but can also 
be targeted for delivery of compounds to M2-polarized macrophages. 
 
TNF-α (Tumor necrosis factor alpha): Pro-inflammatory cytokine produced by 
macrophages and adipocytes that activates NF-κB and induces insulin resistance. 
 
TACE (Tumor necrosis factor-α converting enzyme): Metalloproteinase that 
generates soluble TNF-α. 
 
Y-BGs (Yeast-derived β-glucans): β-D-glucose polysaccharides extracted from the 
cell walls of Saccharomyces cerevisiae that have shown promise in altering obesity 
via IL-10 mediated effects.  
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Rationale for macrophages as therapeutic targets in metabolic disease 
Cells of the immune system have important functions in health and disease. 
Their roles in autoimmune and inflammatory diseases are obvious; however, more 
recently, their contributions to cancer [205], cardiovascular disease [206, 207], 
and diabetes [65, 208, 209], have also been elucidated. Although all cells of the 
immune system can theoretically impact tissue homeostasis and contribute to 
disease, macrophages are particularly important to consider as therapeutic targets 
because they are resident in all tissues and show tremendous plasticity. 
Furthermore, they are phagocytic [210] and thus capable of endocytosing particles 
that are nanometers to micrometers in size. This review will focus on recent 
literature that shows the therapeutic potential of targeting macrophages in 
metabolic diseases as well as novel delivery systems being developed to capitalize 
on their phenotypic variability.  
 
Contribution of macrophages to metabolic disease 
Macrophages are historically understood for their role as recruited and 
differentiated monocytes that respond to acute infection as phagocytes and 
secretors of inflammatory cytokines [210]. Resident macrophages are present in 
every tissue and are involved in development, as well as maintenance of tissue 
homeostasis, and have been given special names based upon their tissue-of-
residence, e.g. adipose tissue macrophages (ATMs) and Kupffer cells of the liver 
(Reviewed in [4, 65]; Figure 47). Macrophages can act as accessory cells and 
positively contribute to tissue homeostasis [211]. Briefly, macrophages secrete 
chemokines, cytokines, growth factors, and extracellular vesicle-encapsulated  
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Figure 47. Tissue Associated Macrophages  
Resident macrophages are known to play critical roles in tissue homeostasis and 
in disease. These macrophages are given special names based upon their tissue-
intrinsic function. Most tissue resident macrophages are yolk sac-derived and self-
renew; however, circulating monocytes can also infiltrate tissues. Macrophages 
from each tissue also have distinct cell surface markers that could ultimately be 
used for tissue specific macrophage targeting in the future [4, 5]. 
 
Arterial Macrophages: Lipid laden foamy macrophages in atherosclerotic 
plaques are thought to contribute to lesion formation due to their accumulation of 
cholesterol and secretion of inflammatory cytokines. In addition, they may 
contribute to plaque instability, intraplaque hemorrhage, and rupture. In this 
setting, targeting them to reduce their inflammatory nature and increase their 
pro-fibrotic tendencies are strategies to improve CVD [7].  
 
Kupffer Cells: Kupffer cells play roles in liver iron handling, bilirubin 
processing, scavenging of gut-derived pathogens, cholesterol metabolism, and 
immune surveillance [8]. When over-activated, they can also be pathogenic by 
accumulating lipid, secreting inflammatory cytokines, and activating stellate cells 
to produce α-smooth muscle actin, leading to fibrosis and ultimately non-alcoholic 
fatty liver disease (NAFLD). Elimination of macrophages is known to reduce 
progression of NAFLD. It should be noted that monocytes can be recruited from 
the circulation to the liver and subsequently differentiate into macrophages; 
however, these have distinct cell surface markers compared to Kupffer cells. 
 
Red pulp macrophages (RPMs): RPMs are responsible for recycling iron 
retrieved from senescent red blood cells following erythrophagocytosis [10]. In 
fact, 10 times more iron is recycled in RPMs than is absorbed by enterocytes. 
Because elevated tissue iron stores are correlated with systemic IR, RPMs could 
be a potential target for metabolic disease in certain settings.   
 
Tumor Associate Macrophages (TAMs):  Myeloid cells are recruited to the 
tumor microenvironment where they can be differentiated into TAMs. They retain 
an M2-like phenotype and are thereby immunosuppressive – preventing immune 
detection and destruction of malignant cells [11]. Thus, their presence is 
associated with increased tumor burden and worsened prognosis. Use of 
mannosylated, siRNA delivery nanoparticles has been recently utilized to activate 
NF-κB in macrophages and is a promising anti-cancer therapy [13]. 
 
Microglia: Macrophages in the brain are called microglia and are essential to 
central nervous system homeostasis [15]. Developmental programming, synapse 
remodeling, phagocytosis of dead cells are among their many functions. Microglial 
activation is a feature of neurodegeneration and also diabetic retinopathy, and 
thus, reducing their inflammatory potential is a potential target for these 
diseases. 
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material that can influence the function of neighboring parenchymal cells. Ongoing 
studies are focused on macrophage-parenchymal cells in tissue homeostasis; 
however, to date, this has most often been studied in the context of disease, e.g. 
inflammatory cytokines can cause IR, rather than how these interactions promote 
tissue health. Thus, many times, the pathogenicity of macrophages derives from 
their ability to modulate the function of neighboring cells – a characteristic that 
can be exploited when considering their potential as therapeutic targets.  
Macrophages are polarized across a broad spectrum, from an M1-like state 
that is considered to be pro-inflammatory, to an M2-like state in which they are 
anti-inflammatory and pro-fibrogenic. This diversity of phenotype is relevant to 
acute infections where macrophages initially fight off pathogens and phagocytose 
dead cells, but then convert their phenotype and subsequently assist in the wound 
healing process. The various properties of macrophages have been reviewed [212], 
but it is important to note that traditional M1 and M2 classification has been 
challenged, and more recent studies have suggested a spectrum of inflammatory 
phenotypes for macrophages [213]. Nonetheless, these same M1-like and M2-like 
properties can be detrimental when exaggerated or unregulated in chronic 
inflammation. For example, excess inflammatory cytokine secretion can lead to IR 
in neighboring cells – a finding particularly relevant in AT. Conversely, excess 
fibrogenic stimulation can lead to fibrosis in diseases such as NAFLD. Thus, when 
considering macrophages as therapeutic targets, one needs to be discerning about 
the phenotype of the macrophages targeted and pathogenesis of the disease 
treated. Although it is now appreciated that macrophages can contribute to the 
development of metabolic diseases, their contributions are tissue-specific and 
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context-dependent. Understanding the complexity and diversity of macrophages is 
also critical.  
 
Macrophages in obesity-related adipose tissue inflammation and IR 
Due to the contribution of M1-like inflammatory macrophages to obesity-
related IR, the selection of macrophage-specific therapeutics should focus on their 
involvement. Potential areas of modification are to reduce M1-like polarization and 
inflammatory cytokine production via targeting of specific cytokines such as tumor 
necrosis factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1 beta (IL-1β), 
or chemokines such as Chemokine (C-C motif) ligands 2, 3, and 5 (CCL2, CCL3, 
and CCL5, respectively). Other inflammatory signal transduction intermediates 
such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
signaling molecules in the inflammasome pathway may prove reasonable targets as 
well. Conversely, increasing the M2-like anti-inflammatory ATM phenotype via 
adiponectin, peroxisome proliferator-activated receptor gamma (PPARγ), or type 2 
cytokines such as Interleukins 4, 13, and 33 (IL-4, IL-13, and IL-33, respectively) is 
an alternative [reviewed in [214]]. There are at least 3 caveats with this strategy 
that should be noted: 1) M1 macrophage content is increased in obese human AT, 
but not to the same degree as mouse adipose [215-218]. 2) Systemic reduction of 
inflammation has not been effective at improving metabolic parameters [214], but 
it is possible that specifically modifying ATMs may be a more viable approach due 
to the paracrine rather than endocrine nature of M1 macrophage interactions with 
nearby parenchymal cells. 3) In early stages of AT expansion, mild inflammation is 
beneficial [219], so the timing of this approach needs to be carefully considered. 
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Despite these caveats, reducing ATM inflammatory potential remains a promising 
avenue for treatment of obesity-accelerated IR and diabetes.  
 
Other macrophage subsets in adipose tissue 
Recently, a new population of metabolically active macrophages (MMe) in 
the AT has been described [220, 221]. Although MMe macrophages secrete pro-
inflammatory cytokines, they have distinct cell surface markers that distinguish 
them from both M1 and M2 macrophages. Specifically, MMes do not express 
CD38, CD319, or CD273, which are traditional M1 markers, but instead express 
ABCA1, CD36, and PLIN2, which are associated with M2 macrophages.  
In addition to MMes, macrophages with iron-related phenotypes have also 
been identified in AT. Iron-handling macrophages were first identified in 
atherosclerotic plaques [222-225] and have been shown to be M2-like and to 
express high levels of mannose receptor and the haptoglobin/hemoglobin receptor, 
CD163. They have been given names such as M(Hb) and Mhem and are reviewed in 
[226]. In plaques, these iron-handling macrophages are considered to play a role in 
clearing intra-plaque hemorrhage. Our laboratory has found a similar population 
of iron handling macrophages in AT that we call MFehi [67]. These MFehi 
macrophages have a 2-fold increase in iron content and in iron handling genes 
compared with non iron-handling AT macrophages. Interesting, they have a strong 
M2-like phenotype with high expression of mannose receptor and CD163 – just 
like the M(Hb) and Mhem macrophages, even in the presence of excess iron. Their 
relevance to AT homeostasis and protection from IR is under investigation, but 
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they highlight the point that both M1-like and M2-like macrophages could be 
targets of therapy for obesity-related metabolic disorders.  
 
Hepatic macrophages in nonalcoholic fatty liver disease 
Similar to the AT transition, hepatic macrophages undergo changes in 
polarization, recruitment, and proliferation during the pathogenesis of NAFLD 
[227]. Hepatic macrophages are dynamic players in maintaining liver homeostasis, 
via protection against bacteria and microbes from the intestine and restoring tissue 
integrity following liver injury [reviewed in [8]]. The liver contains a number of 
distinct macrophage subsets important for liver disease, with embryonic-derived 
Kupffer cells and monocyte-derived macrophages being the primary subsets 
driving the progression of NAFLD. Kupffer cells are the resident macrophages of 
the liver and make up ~20-25% of the non-parenchymal cell content [228]. NAFLD 
develops due to long-term high carbohydrate or fat consumption, resulting in 
hepatocyte lipid accumulation and cell death. The inflamed hepatocytes secrete 
chemokines, such as CCL2 and TNF-α, leading to the activation and proliferation of 
Kupffer cells and conversion to what could be considered an M1-like phenotype, 
with expression and secretion of cytokines such as IL-6, IL-1β, TNF-α, and 
inducible nitric oxide synthase 2 (iNOS2) [229]. In addition inflamed hepatocytes 
and Kupffer cells signal for the infiltration of CCR2+Ly6C+ monocytes that 
differentiate into monocyte-derived macrophages, also expressing an M1 
phenotype [230, 231].  
Recently, macrophage inflammation has been targeted for treatment of 
NAFLD. Impairment of recruitment and/or depletion of hepatic macrophage 
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subsets have been shown to successfully suppress hepatic steatosis and 
inflammation in mouse models of NAFLD [232, 233]. It has been shown that 
pediatric NAFLD prognosis could be improved through treatment with 
docosahexaenoic acid due to its effects on macrophage polarization, pushing them 
toward an M2-like phenotype [234]. Dietary carotenoids have also been proposed 
for NAFLD treatment due to their effects on macrophage polarization [reviewed in 
[235]]. More recently, altering the polarization state of hepatic macrophages to an 
M2 phenotype by increasing PPARγ activity was found to reduce NAFLD in mice 
[229].  
 
Macrophages in atherosclerosis 
Like AT and the liver, the healthy artery wall contains resident macrophages 
[236], and in hyperlipidemic conditions, the recruitment of additional 
macrophages leads to atherosclerotic lesion formation [7]. High fat feeding and 
hyperlipidemia can both induce myelopoiesis in the bone marrow and recruitment 
of monocytes into the intimal space [237, 238]. Once there, they differentiate into 
macrophages and express scavenger receptors allowing them to endocytose 
oxidized lipids. This lipid accumulation results in foamy macrophages that are 
highly inflammatory and that also send chemotactic signals to recruit additional 
monocytes, exacerbating the lipid-enriched inflammatory milieu [239]. Recently, a 
subset of arterial macrophages [Mhem, M(Hb)] have been shown to express 
receptors involved in heme scavenging and can clear debris during intraplaque 
hemorrhage as discussed earlier [240]. In addition, a novel macrophage 
population that uniquely responds to oxidatively modified lipids in the 
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atherosclerotic plaque, called “Mox”, has been identified [241]. Understanding the 
biology of these unique subsets of arterial macrophages and developing strategies 
similar to those suggested for AT, i.e. reduction of their inflammatory potential, 
may provide therapeutic opportunities for atherosclerosis. Additionally, decreasing 
their ability to take up lipid or increasing their ability to efflux lipid are other 
possibilities. In fact, mannose functionalized nanoparticles have recently been 
utilized to deliver therapeutic molecules to plaque macrophages in a mouse model 
of atherosclerosis [242]. Although, this is a very new area of research, the high level 
of mannose receptor expression on M(Hb) and Mhem cells, could provide a 
method to target them with mannosylated particles in order to dampen 
inflammation and improve their iron handling phenotype. 
 
Macrophages as a therapeutic target in metabolic disease 
Targeting strategies: Intracellular access 
Currently, most macrophage-targeted therapeutic strategies provide 
specificity by capitalizing on receptor-mediated phagocytosis. Compounds 
designed to encapsulate therapeutics can have surface modifications that are 
recognized by receptors on macrophages. There are defining receptors such as 
F4/80, CD11b, and CD68 that are expressed on all macrophages [243-245], but 
subpopulations can additionally express others – such as those for mannose, lectin, 
adenosine [246], and folate [247]. Although not exclusively macrophage-specific, 
they allow targeting of cells of particular phenotypes and activation states. This 
receptor-focused approach offers a direct route of import into macrophages while 
minimizing off-target effects.  
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There are at least three methods of internalization that can be exploited for 
delivery purposes [reviewed in [248]]. 1) Activation of therapeutic agents in the 
acidic lysosomal compartment: Once recognized and engulfed, entrapped particles 
are packaged into a phagosome prior to fusion with destructive lysosomes. 
Utilizing the microenvironment of the phagosome or lysosome to initiate 
therapeutic activity is promising, but has been primarily limited to nanoparticle 
encapsulation approaches. In these strategies, the acidic lysosomal interior 
initiates breakdown of the nanoparticle capsule and release of its contents [249] 
Alternatively, lysosomal enzymes degrade the nanoparticle shell to release core 
contents [250]. 2) Cytoplasmic delivery via endocytosis and lysosomal escape: 
Another strategy to avoid phagocytic destruction is to design particles that escape 
phagosomes after endocytosis but prior to fusion with the lysosome [251]. 3) 
Utilization of endocytic receptors: A third strategy takes advantage of active 
transport into the macrophage mediated by coat proteins, such as clathrin and 
caveolin [252]. Once a particle has entered the intracellular space, it can deliver its 
phenotype/function altering cargo. Methods to accomplish this in macrophages are 
discussed below.  
 
Therapeutic strategies: Changing the role of the macrophage 
Once inside the macrophage, therapeutic strategies are diverse - depletion, 
proliferation, inflammation, and gene silencing are commonly used. Approaches 
that modulate macrophage number often aim to deplete macrophages by inducing 
apoptosis following accumulation of toxic particles that are released into the 
macrophage [253]. Targeting proliferation may also reduce macrophage number 
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[254], and could be relevant for atherosclerosis; however, macrophages are often 
recruited in the context of obesity, so this strategy may not be as useful for IR. 
Modification of inflammatory signal transduction pathways inside the macrophage 
is another approach. By introducing anti-inflammatory agents to the macrophage 
cytoplasm, inflammatory cytokine production and release can be modulated [255]. 
Perhaps the most attractive approach to modifying macrophage polarization is to 
reduce inflammatory gene expression through RNA interference, as multiple genes 
can be downregulated simultaneously. Potential targets include inflammatory 
mediators such as cytokines, e.g TNF-α, IL-6, IL-1β; chemokines, e.g. CCL2, CCL3, 
CCL5; and transduction targets involved in promoting inflammation such as 
members of the NF-κB signaling cascade [256, 257]. These therapeutic strategies, 
coupled with techniques to target specific macrophage subsets, offer a variety of 
ways to modulate macrophage number and activity at the site of metabolic disease. 
 
Methods of delivery 
Nanoparticles 
Nanoparticle design and delivery is a logical strategy for macrophage 
therapeutics. By definition, nanoparticles are small agents ranging from 1-1000 
nm. Their surface coating dictates whether they target a particular cell type – due 
to receptor-mediated specificity – or an entire tissue due to chemical properties 
that encourage attraction to that depot [258]. This approach provides target 
specificity that aims to minimize toxicity and off-target effects. One area of 
particular interest is development of nanoparticles that target antigen presenting 
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cells, such as macrophages and dendritic cells, via receptors of the C-type lectin 
family, [reviewed in [259]]. 
In one recent example, polysaccharide-based delivery systems were utilized 
to target inflammatory ATMs in obese mice [260]. The 4-30 nm particles were 
made with dextran and were readily taken up by macrophages following 
recognition by dextran-binding C-type lectins and scavenger receptors. In lean 
mice, the nanoparticles preferentially accumulated in liver after intraperitoneal 
(IP) injection, but in obese mice they accumulated in the adipose depots. The 
authors showed that ~90% of the cells taking up the particles in gonadal, perirenal, 
and subcutaneous AT were of myeloid origin. The nanocarriers were used to 
deliver the anti-inflammatory drug, dexamethasone, specifically to the obesity-
associated inflammatory macrophages. Upon delivery, there was a marked 
decrease in pro-inflammatory genes, Tnf , Il6, and Ccl2. Although, these 
preliminary studies show promise in the nontoxic treatment of chronic 
inflammation in obese AT, the IP delivery method is not realistic for clinical use. 
The investigators suggest that extended release will be necessary in order to 
minimize the invasiveness of delivery, but other modes of delivery will need to be 
explored, and AT specificity will need to be confirmed regardless of the 
administration route.   
There are nanoparticle technologies that have targeted macrophage 
receptors in other diseases, but not yet in metabolic disease. For example, 
superparamagnetic iron oxide nanoparticles (SPIONs) have traditionally been used 
as imaging tools, but now have also been shown to impact M2 macrophages by 
altering their activation state and iron handling capabilities [261].  The M2-like 
! 101 
phenotype of iron-handling macrophages means that their use as a therapeutic 
target must be considered differently than M1-like macrophages. With regard to 
MFehi, Mhem, and M(Hb) macrophages, a potential use for SPIONs could be to 
induce an iron recycling phenotype and/or increase their anti-inflammatory 
phenotype. Along these lines, “click” chemistry has been used to create 
mannosylated nanoparticles that deliver siRNA specifically to M2-polarized TAMs 
that express mannose receptor on their surface [262]. While these The ability of 
these nanoparticles to specifically target the M2 macrophages that are present in 
lean AT makes them a potentially promising technology for further exploration. 
More research is needed regarding the roles of MFehi, Mhem, and M(Hb) 
macrophages in AT and the artery wall so that siRNA therapy can be targeted to 
pathways that are relevant to these iron-handling macrophages. 
 
Liposomes  
Liposomes are a third drug delivery platform that has been investigated. 
Liposomes are phospholipid vesicles, about 15-1000 nm in size, that can carry 
either hydrophilic or lipophilic drugs in their bilayer membrane or core, 
respectively. The encapsulation design allows for drug protection and stabilization; 
one method of which is PEGylation, which increases circulation time [263]. As with 
nanoparticles, liposome shells can be engineered with ligands or antibodies to 
target specific macrophage phenotypes based on receptor specificity. For example, 
F4/80-targeted liposomes would go to all macrophages, while IL-6 receptor or 
CD163-targeted liposomes would be taken up by M1 or M2 polarized macrophages, 
respectively. Additionally, the contents of the liposomes can be altered. These 
! 102 
design features allow for more effective and efficient targeting because the outer 
shell of the compound can be changed depending on where it needs to go, while the 
inner contents can be altered according to therapeutic needs. While advances have 
been made in the design of liposomes [reviewed in [264-266]], clinical usage has 
proven difficult. Due to the complexity of liposome compounds, the associated 
trials are typically longer and more complex, which leads to cost burden. Off-target 
effects of treatment are also common because of leakiness of the liposome and 
degradation of the particles through circulation. Nonetheless, liposomes remain 
attractive therapeutics as there are many ways that they can be engineered to 
target macrophages in metabolic disease.  
Liposomes can enter macrophages purely because of the cells’ phagocytic 
properties. Clodronate-loaded liposomes are used to deplete macrophages by 
inducing apoptosis when internalized. This technology has been historically used 
in many tissues, but in 2011 depletion of visceral ATMs with consequent effects on 
tissue health was shown. IP injection of clodronate liposomes, resulted in an 
improved glucose and insulin tolerance that was associated with increased 
circulating adiponectin, an insulin sensitizing adipokine [70]. In 2013, another 
study showed similar data: under the same conditions – animals fed a high fat diet 
gained less weight, showed improved glucose tolerance and decreased fasting 
glucose, insulin, and free fatty acid levels, compared to control groups [267]. 
Notably, these studies potentially represent an additional disease preventative 
approach. Current efforts focus on lifestyle changes in diet and exercise, but 
adjuvant therapy to reduce the inflammatory environment of AT by targeting 
ATMs should be considered. Nonetheless, this research tool provides mechanistic 
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insight into obesity-related disease progression and is a method that can be further 
optimized to more specifically target macrophage subsets involved in metabolic 
disease.  
As with the nanoparticle technologies, discoveries in liposome delivery 
outside of the metabolism field may prove interesting for the treatment of 
metabolic disease. For example, CD163 antibody coated liposomes were shown to 
be taken up by CD163+ monocytes in vitro and to kill cells when loaded with 
doxorubicin [268]. CD163+ macrophages are resident in lean healthy AT, but their 
numbers are overshadowed during obesity related inflammation. If the healthy 
cells can be targeted and encouraged to proliferate, the obese tissue 
microenvironment can conceivably be therapeutically altered to resemble its lean, 
and healthier, counterpart.  
 
Glucan shell microparticles 
β-glucans are sugars most commonly found in the cell walls of bacteria. 
Dectin-1, a macrophage receptor for β-glucans has been proposed as a potential 
therapeutic with antitumor and antimicrobial activity [269, 270]. Yeast-derived β-
glucans (Y-BGs) have been reviewed recently and are known to have beneficial 
effects in models of obesity, allergy, and cancer [271]. For example, orally 
administrated Y-BGs induced expression of the anti-inflammatory cytokine, IL-10, 
in the AT of obese humans and increased serum IL-10 levels [272]. Once taken up 
by macrophages, Y-BGs appear to cause increased reactive oxygen species (ROS) 
formation and phagosomal maturation, ultimately resulting in the induction of 
autophagy [273]. A recent study suggests IL-10 is an important mediator of 
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macrophage autophagy necessary for removing dysfunctional mitochondria [274]. 
Taken together, these findings suggest Y-BGs promote anti-inflammatory activity 
in macrophages through an IL-10 mediated mechanism.  
Interestingly, Y-BGs have been used as unique encapsulation tools that can 
target macrophages in an activation-independent manner. These 2-4 µm hollow 
particles are able to encapsulate potential therapeutics, including siRNA and small 
molecules [275-277]. For example, glucan shells have been utilized to encapsulate 
gene-silencing molecules for macrophage targeted therapies. Orally delivered β1,3-
d-glucan-encapsulated siRNA particles (GeRPs) containing siRNA directed toward 
mitogen activated protein kinase kinase kinase kinase 4 (Map4k4) reduced 
systemic inflammation by reducing Tnf  mRNA in macrophages [275]. In this 
design, the siRNA is anchored to Endo-Porter peptide, which simplifies compound 
preparation and also facilitates release of internalized GeRPs into the macrophage 
cytoplasm. This peptide-facilitated phagosomal escape is critical for siRNA to reach 
the cytoplasm where it can function to silence inflammatory genes. Macrophages 
exposed to orally delivered GeRPs migrated to other tissues and resulted in a 40-
80% knockdown of Map4k4 expression depending on tissue site. These data also 
suggest that delivery of GeRPs to specific tissue sites can be carried out by the 
macrophages themselves upon migration to peripheral tissues. IP injection of 
GeRPs resulted in specific delivery to epididymal ATMs in obese mice, resulting in 
silencing of Tnf-α and Opn [278]. While these studies show promise, IP delivery of 
GeRPs would not be favorable for clinical use. Upon further analysis of their 
efficacy, the investigators should determine whether other modes of delivery are 
possible.  
! 105 
Oligopeptide Complexes 
Oligopeptides have been known for decades to display tissue specificity 
[279-281]. Many tissues are difficult to target for non-viral mediated gene delivery, 
and oligopeptides complexed with gene modulating molecules are an attractive 
solution. These oligopeptide complexes exhibit specificity by utilizing peptide-
bound oligonucleotide sequences designed to target specific cell populations and 
are complexed with modulatory molecules, such as siRNA or shRNA, that function 
by silencing genes. One such oligopeptide gene carrier has been designed and is 
effectively taken up by mature adipocytes through binding a cell surface protein 
called prohibitin [280]. However, ATMs have also been shown to express 
prohibitin, and these oligopeptide gene carriers were found in the the stromal 
vascular fraction of AT that contains immune cells. This unexpected finding may 
prove to be beneficial in attempts to specifically deliver non-viral gene altering 
technology to adipose depots and ATMs. 
Another potential way to therapeutically target ATMs is through tumor 
necrosis factor-α converting enzyme (TACE) oligopeptides. TACE is an anti-
inflammatory metalloproteinase, which is critical for generating soluble TNF-α, 
and therefore presents a remarkable opportunity for disrupting TNF-α mediated 
inflammation [282]. Complexes of TACE shRNA (shTACE) and adipocyte-
targeting sequence (ATS-9R) oligopeptides have been produced and are specifically 
taken up by visceral ATMs following IP injection. These complexes display 
specificity for AT, and function by silencing TACE, resulting in the cell’s inability to 
generate soluble TNF-α. Accumulation of injected oligopeptides in visceral ATMs 
without accumulation in the spleen or liver after 4 hours has been observed [281]. 
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Although shTACE oligopeptide complexes are enzymatically degraded, 8 repeated 
injections over a month long period resulted in improved insulin sensitivity and 
glucose tolerance, which was attributed to reductions in adipose TACE activity.  
 
Concluding remarks and future perspectives 
Macrophages have become a unique target for treating metabolic disease 
since the discovery of their importance in metabolic tissues and their change in 
phenotype upon disease progression. This review presents discoveries that couple 
the ability to alter macrophage function with the technologies that ensure their 
specific targeting. There is ongoing research to define specific macrophage subsets, 
identify surface markers unique to these subsets, and capitalize on their unique 
properties to target specific functions. Many of the delivery systems described in 
this review can be engineered to transport gene-silencing agents such as siRNA; 
however; challenges remain in successfully eliminating the targeted gene 
expression. While CRISPR-Cas9 technology can not yet be used in vivo [283], it 
would be interesting to determine whether this technology could be delivered 
specifically to tissue macrophage subsets in order to alter their polarization and 
functional phenotype. Additionally, it has recently been elucidated that epigenetic 
regulation is involved in macrophage polarization, [284]. Targeting epigenetic 
modifications via genetic or pharmacological perturbation is another promising 
area of research. 
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While strides have been made in elucidating mechanisms involved in 
maintaining healthy macrophages in metabolic tissues, questions still remain 
regarding the therapeutic potential and feasibility of specifically treating 
macrophages in metabolic disease (see Outstanding Questions). Ultimately, the 
future of macrophage-specific treatment relies on continued efforts to identify and 
produce therapeutics that can be specifically targeted to cells of the appropriate 
phenotype and tissue location.  
 
  
Figure 48. Outstanding Questions 
• Can we identify and utilize unique macrophage markers to provide 
tissue-specific therapy? 
• Will antisense oligonucleotide therapies targeting macrophages be 
useful for treatment of metabolic disease? 
• Are there less expensive and more streamlined methods to design 
liposomes that target specific phenotypes of macrophages in metabolic 
tissues? 
• What are the long-term effects of all of these novel strategies?  
• Modulation of epigenetic programming and permanent genetic 
alteration via CRISPR are both innovative and cutting edge techniques. 
What is the future of these discoveries as it relates to metabolic disease? 
How responsive will the public be to therapeutics that alter the genome 
or epigenome in particular cells? 
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